DK1087013T3 - Immunoglobuliner uden lette kæder - Google Patents

Immunoglobuliner uden lette kæder

Info

Publication number: DK1087013T3
Authority: DK; Denmark
Prior art keywords: immunoglobulins; light chains; antigen binding; polypeptide chains; immunoglobulin
Prior art date: 1992-08-21

Application number

DK00127968T

Other languages

English (en)

Inventor

Cecile Casterman

Raymond Hamers

Original Assignee

Univ Bruxelles

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-08-21

Filing date

1993-08-18

Publication date

2009-05-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26132410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1087013(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-08-21 Priority claimed from EP92402326A external-priority patent/EP0584421A1/en

1993-08-18 Application filed by Univ Bruxelles filed Critical Univ Bruxelles

2009-05-11 Application granted granted Critical

2009-05-11 Publication of DK1087013T3 publication Critical patent/DK1087013T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK00127968T 1992-08-21 1993-08-18 Immunoglobuliner uden lette kæder DK1087013T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP92402326A EP0584421A1 (en)	1992-08-21	1992-08-21	Immunoglobulins devoid of light chains
EP93401310		1993-05-21
PCT/EP1993/002214 WO1994004678A1 (en)	1992-08-21	1993-08-18	Immunoglobulins devoid of light chains

Publications (1)

Publication Number	Publication Date
DK1087013T3 true DK1087013T3 (da)	2009-05-11

Family

ID=26132410

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
DK05008358.3T DK1589107T3 (da)	1992-08-21	1993-08-18	Immonuglobuliner uden lette kæder
DK93919098.9T DK0656946T4 (da)	1992-08-21	1993-08-18	Immunoglobuliner uden lette kæder
DK05020889.1T DK1621554T4 (da)	1992-08-21	1993-08-18	Immunoglobuliner blottet for lette kæder
DK04077639.5T DK1498427T3 (da)	1992-08-21	1993-08-18	Immunoglobuliner, som ikke har lette kæder
DK00127968T DK1087013T3 (da)	1992-08-21	1993-08-18	Immunoglobuliner uden lette kæder

Family Applications Before (4)

Application Number	Title	Priority Date	Filing Date
DK05008358.3T DK1589107T3 (da)	1992-08-21	1993-08-18	Immonuglobuliner uden lette kæder
DK93919098.9T DK0656946T4 (da)	1992-08-21	1993-08-18	Immunoglobuliner uden lette kæder
DK05020889.1T DK1621554T4 (da)	1992-08-21	1993-08-18	Immunoglobuliner blottet for lette kæder
DK04077639.5T DK1498427T3 (da)	1992-08-21	1993-08-18	Immunoglobuliner, som ikke har lette kæder

Country Status (13)

Country	Link
US (5)	US6015695A (da)
EP (6)	EP0656946B2 (da)
JP (4)	JP3444885B2 (da)
AT (5)	ATE420178T1 (da)
AU (1)	AU701578B2 (da)
CA (1)	CA2142331C (da)
DE (6)	DE69334305D1 (da)
DK (5)	DK1589107T3 (da)
ES (5)	ES2325541T3 (da)
FI (3)	FI115462B (da)
GR (1)	GR3037024T3 (da)
PT (5)	PT1498427E (da)
WO (1)	WO1994004678A1 (da)

Families Citing this family (1305)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6765087B1 (en) *	1992-08-21	2004-07-20	Vrije Universiteit Brussel	Immunoglobulins devoid of light chains
US6838254B1 (en)	1993-04-29	2005-01-04	Conopco, Inc.	Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
EP0739981A1 (en)	1995-04-25	1996-10-30	Vrije Universiteit Brussel	Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US20040248201A1 (en) *	1996-06-27	2004-12-09	Serge Muyldermans	Recognition molecules interacting specifically with the active site or cleft of a target molecule
CA2258518C (en) *	1996-06-27	2011-11-22	Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw	Recognition molecules interacting specifically with the active site or cleft of a target molecule
WO1998015581A1 (en) *	1996-10-10	1998-04-16	Cytel Corporation	Carbohydrate purification using ultrafiltration, reverse osmosis and nanofiltration
US20030228310A1 (en) *	1996-12-23	2003-12-11	Advanced Biotherapy, Inc.	Treatment of skin diseases
EP1051493A2 (en) *	1998-01-26	2000-11-15	Unilever Plc	Method for producing antibody fragments
DE69920897T2 (de) *	1998-04-28	2005-10-13	Smithkline Beecham Corp.	Monoklonale antikörper mit verringerter immunisierungsfähigkeit
BR0009866A (pt) *	1999-04-22	2002-01-08	Unilever Nv	Método de inibição de infecção viral, uso de uma proteìna de ligação de antìgeno monovalente, produto alimentìcio, composição farmacêutica ou cosmética, proteìna de ligação de antìgeno monovalente, sequência de nucleotìdeos, vetor de expressão, célula hospedeira, e, métodos de seleção e de indentificação de uma proteìna de ligação de antìgeno
US6924359B1 (en) *	1999-07-01	2005-08-02	Yale University	Neovascular-targeted immunoconjugates
BR0012711A (pt)	1999-07-27	2002-04-09	Unilever Nv	Composição detergente enzimática, e, processos para aumentar a atividade e / ou a estabilidade de uma oxidorredutase dependente de co-fator e para branquear manchas presentes em tecidos
DE60019309T2 (de) *	1999-09-16	2005-09-22	Unilever Plc	Abgabesystem für ein mittel gegen schuppen
EP1088892A1 (en) *	1999-09-24	2001-04-04	Vlaams Interuniversitair Instituut voor Biotechnologie vzw.	Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
US6479280B1 (en)	1999-09-24	2002-11-12	Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw	Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
DK1242460T3 (da)	1999-11-29	2006-12-11	Unilever Nv	Immobilisering af proteiner ved hjælp af et polypeptidsegment
EP1118669A3 (en) *	1999-12-17	2001-08-29	Unilever Plc	Production of camelid antibodies in plants
ATE428733T1 (de)	2000-03-14	2009-05-15	Unilever Nv	Variabele domänen der schweren kette eines antikörpers gegen menschliche ernährungslipasen und deren verwendungen
US6696620B2 (en) *	2000-05-02	2004-02-24	Epicyte Pharmaceutical, Inc.	Immunoglobulin binding protein arrays in eukaryotic cells
CA2380443C (en)	2000-05-26	2013-03-12	Ginette Dubuc	Single-domain antigen-binding antibody fragments derived from llama antibodies
EP1328626B1 (en)	2000-05-26	2013-04-17	National Research Council Of Canada	Single-domain brain-targeting antibody fragments derived from llama antibodies
US20050196755A1 (en) *	2000-11-17	2005-09-08	Maurice Zauderer	In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US7858559B2 (en) *	2000-11-17	2010-12-28	University Of Rochester	In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US20060064782A1 (en) *	2000-12-18	2006-03-23	Conopco, Inc.	Production of antibodies
EP1368380B1 (en)	2000-12-19	2009-09-02	Unilever N.V.	Stabilisation of heavy chain Camelid antibodies with potassium salts
ATE519783T1 (de) *	2000-12-22	2011-08-15	Grad Carole Legal Representative Of Kaplan Howard	ßPHAGE DISPLAYß BIBLIOTHEKE VON MENSCHLICHEN VH FRAGMENTEN
EP2198882A3 (en)	2001-01-12	2010-10-13	Novartis Vaccines and Diagnostics, Inc.	Nucleic acid mucosal immunization
US7829084B2 (en) *	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
US20050069538A1 (en) *	2003-09-18	2005-03-31	Gregorio Aversa	Therapeutic binding molecules
US20040058445A1 (en) *	2001-04-26	2004-03-25	Ledbetter Jeffrey Alan	Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US20040062768A1 (en) *	2001-06-05	2004-04-01	Advanced Biotherapy, Inc.	Compositions and methods for treating hyperimmune response in the eye
US6861056B2 (en) *	2001-06-05	2005-03-01	Advanced Biotherapy, Inc.	Compositions and methods for treating hyperimmune response in the eye
US20050152902A1 (en) *	2001-06-05	2005-07-14	Advanced Biotherapy, Inc.	Treatment of diabetic retinopathy
US20040086508A1 (en) *	2001-06-05	2004-05-06	Advanced Biotherapy, Inc.	Treatment of organ transplant rejection
JP2005289809A (ja)	2001-10-24	2005-10-20	Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw)	突然変異重鎖抗体
EP1456237A2 (en) *	2001-12-21	2004-09-15	Vlaams Interuniversitair Instituut voor Biotechnologie vzw.	Method for cloning of variable domain sequences
EP1461085A2 (en) *	2002-01-03	2004-09-29	Vlaams Interuniversitair Instituut voor Biotechnologie vzw.	Immunoconjugates useful for treatment of tumours
EP1474444A1 (en)	2002-01-10	2004-11-10	Vlaams Interuniversitair Instituut voor Biotechnologie vzw.	A novel splice variant of myd88 and uses thereof
AU2002333502A1 (en)	2002-02-10	2003-09-04	Apoxis Sa	Fusion constructs containing active sections of tnf ligands
US20030219436A1 (en) *	2002-03-15	2003-11-27	Ledbetter Jeffrey A.	Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
US9321832B2 (en)	2002-06-28	2016-04-26	Domantis Limited	Ligand
EP1517921B1 (en) *	2002-06-28	2006-06-07	Domantis Limited	Dual specific ligands with increased serum half-life
CA2894009C (en)	2002-07-15	2016-12-06	Board Of Regents, The University Of Texas System	Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment
EP1527346B1 (en)	2002-08-07	2011-06-08	Ablynx N.V.	Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
ES2381617T5 (es)	2002-08-14	2016-02-24	Macrogenics, Inc.	Anticuerpos específicos frente a FcgammaRIIB y sus procedimientos de uso
GB0219720D0 (en) *	2002-08-23	2002-10-02	Univ Aberdeen	Polypeptide
US20040052790A1 (en) *	2002-09-18	2004-03-18	Advanced Biotherapy, Inc.	Treatment of schizophrenia
NZ540194A (en)	2002-11-08	2008-07-31	Ablynx Nv	Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US9320792B2 (en)	2002-11-08	2016-04-26	Ablynx N.V.	Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US20060034845A1 (en)	2002-11-08	2006-02-16	Karen Silence	Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
EP1558647B1 (en)	2002-11-08	2015-06-10	Ablynx N.V.	Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
GB0230203D0 (en) *	2002-12-27	2003-02-05	Domantis Ltd	Fc fusion
WO2004062551A2 (en)	2003-01-10	2004-07-29	Ablynx N.V.	RECOMBINANT VHH SINGLE DOMAIN ANTIBODY FROM CAMELIDAE AGAINST VON WILLEBRAND FACTOR (vWF) OR AGAINST COLLAGEN
EP1437764A1 (en) *	2003-01-10	2004-07-14	S.O.I. Tec Silicon on Insulator Technologies S.A.	A compliant substrate for a heteroepitaxy, a heteroepitaxial structure and a method for fabricating a compliant substrate
KR20110094361A (ko)	2003-04-11	2011-08-23	메디뮨 엘엘씨	재조합 ｉｌ９ 항체 및 그의 용도
PL1639011T3 (pl)	2003-06-30	2009-05-29	Domantis Ltd	Pegilowane przeciwciała jednodomenowe (dAb)
US7754209B2 (en)	2003-07-26	2010-07-13	Trubion Pharmaceuticals	Binding constructs and methods for use thereof
LT3095793T (lt)	2003-07-28	2020-07-10	Genentech, Inc.	Baltymo a išplovimo sumažinimas afininės baltymo a chromatografijos metu
US20050221383A1 (en)	2003-08-08	2005-10-06	Choong-Chin Liew	Osteoarthritis biomarkers and uses thereof
EP1687452A4 (en) *	2003-09-30	2008-08-06	Centocor Inc	HUMAN HINGE-CORE MIMETICORPS, COMPOSITIONS, METHODS AND APPLICATIONS THEREOF
CN1878568A (zh)	2003-11-05	2006-12-13	盘林京有限公司	Cdim结合抗体的增强的b细胞细胞毒性
EP2251357A1 (en)	2003-11-07	2010-11-17	Ablynx N.V.	Camelidae single domain antibodies VHH directed against epidermal growth factor receptor and uses therefor
CA2547635C (en) *	2003-12-12	2016-02-09	Jeffrey Schlom	A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1
US7785903B2 (en)	2004-04-09	2010-08-31	Genentech, Inc.	Variable domain library and uses
WO2005105984A2 (en) *	2004-04-12	2005-11-10	The Trustees Of The University Of Pennsylvania	Culture conditions and growth factors affecting fate determination, self-renewal and expansion of mouse spermatogonial stem cells
EP1750759A4 (en) *	2004-06-04	2008-06-04	Genencor Int	SCREENING PROCEDURE USING ANTIBODY HEAVY CHAINS
US20050276806A1 (en) *	2004-06-15	2005-12-15	Advanced Biotherapy, Inc.	Treatment of autism
US20050276807A1 (en) *	2004-06-15	2005-12-15	Advanced Biotherapy, Inc.	Treatment of acne
GB2416768A (en) *	2004-07-22	2006-02-08	Univ Erasmus	Heavy chain immunoglobulin complexes
SG188080A1 (en)	2004-07-22	2013-03-28	Univ Erasmus Medical Ct	Binding molecules
US20060177445A1 (en) *	2004-08-16	2006-08-10	Boris Skurkovich	Treatment of inflammatory skin diseases
US7563443B2 (en) *	2004-09-17	2009-07-21	Domantis Limited	Monovalent anti-CD40L antibody polypeptides and compositions thereof
RU2401842C2 (ru)	2004-10-08	2010-10-20	Домантис Лимитед	Антагонисты и способы их применения
US7462454B2 (en)	2004-10-12	2008-12-09	Advanced Biotherapy, Inc.	Treatment of herpes
KR20070084170A (ko) *	2004-10-13	2007-08-24	아블린쓰 엔.브이.	알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드
AU2005299355A1 (en)	2004-10-27	2006-05-04	Medimmune, Llc	Modulation of antibody specificity by tailoring the affinity to cognate antigens
EP1836500B1 (en)	2005-01-14	2010-07-07	Ablynx N.V.	METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS
CA2595682A1 (en) *	2005-01-31	2006-08-03	Ablynx N.V.	Method for generating variable domain sequences of heavy chain antibodies
WO2006086242A2 (en)	2005-02-07	2006-08-17	Genenews, Inc.	Mild osteoarthritis biomarkers and uses thereof
AU2006213686A1 (en)	2005-02-09	2006-08-17	Avi Bio Pharma, Inc.	Antisense composition and method for treating muscle atrophy
CA2599465A1 (en)	2005-03-11	2006-09-14	Syngenta Limited	Antibody based rodenticide
CA2609702C (en)	2005-04-28	2013-05-28	Ventana Medical Systems, Inc.	Antibody conjugates via heterobifunctional peg linkers
WO2006116742A2 (en) *	2005-04-28	2006-11-02	Ventana Medical Systems, Inc.	Fluorescent nanoparticles conjugated to antibodies via a peg linker
HUE045710T2 (hu)	2005-05-18	2020-01-28	Ablynx Nv	Javított, alfa tumor nekrózis faktor elleni nanobodies
JP4986997B2 (ja)	2005-05-20	2012-07-25	アブリンクスエン．ヴェー．	凝集媒介障害の治療における改良ナノボディ（商標）
DE102005023617A1 (de)	2005-05-21	2006-11-23	Aspre Ag	Verfahren zum Mischen von Farben in einem Display
PT1912675E (pt) *	2005-07-25	2014-05-09	Emergent Product Dev Seattle	Moléculas de ligaçao especificas para cd37 e especificas para cd20
CA2620802A1 (en)	2005-08-31	2007-03-08	Schering Corporation	Engineered anti-il-23 antibodies
NZ566424A (en)	2005-09-01	2011-10-28	Schering Corp	Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
EP1943341A4 (en) *	2005-09-27	2010-07-07	Ca Nat Research Council	BLOOD-BRAIN-SPEED-EPITOPES AND USES THEREOF
AU2006297304B2 (en) *	2005-09-29	2012-05-17	Medimmune, Llc	Method of identifying membrane LG specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
US7526409B2 (en) *	2005-10-07	2009-04-28	Oracle International Corporation	Automatic performance statistical comparison between two periods
GB0521139D0 (en)	2005-10-18	2005-11-23	Univ Sheffield	Therapeutic agent
JP5237817B2 (ja)	2005-10-21	2013-07-17	ジーンニュースインコーポレーティッド	バイオマーカー産物レベルを疾患に相関させるための方法および装置
GB0522460D0 (en) *	2005-11-03	2005-12-14	Prendergast Patrick T	Composition and method for the treatment of avian influenza
US20070117153A1 (en)	2005-11-23	2007-05-24	Christopher Bieniarz	Molecular conjugate
US10183986B2 (en)	2005-12-15	2019-01-22	Industrial Technology Research Institute	Trimeric collagen scaffold antibodies
WO2007082899A1 (en)	2006-01-17	2007-07-26	Vib Vzw	Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
EP1976991A1 (en) *	2006-01-24	2008-10-08	Domantis Limited	Fusion proteins that contain natural junctions
TWI417301B (zh)	2006-02-21	2013-12-01	Wyeth Corp	對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en)	2006-02-21	2007-12-16	Wyeth Corp	Methods of using antibodies against human IL-22
US7504106B2 (en) *	2006-03-14	2009-03-17	Boris Skurkovich	Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
WO2007110219A1 (en) *	2006-03-27	2007-10-04	Ablynx N.V.	Medical delivery device for therapeutic proteins based on single domain antibodies
EP2010910A2 (en) *	2006-04-21	2009-01-07	Wyeth	Differential expression profiling analysis of cell culture phenotypes and the uses thereof
AU2007247137A1 (en)	2006-05-02	2007-11-15	Actogenix N.V.	Microbial intestinal delivery of obesity related peptides
WO2007146968A2 (en)	2006-06-12	2007-12-21	Trubion Pharmaceuticals, Inc.	Single-chain multivalent binding proteins with effector function
CA2655080A1 (en)	2006-06-14	2007-12-21	Macrogenics, Inc.	Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
AU2007281876B2 (en)	2006-06-26	2013-09-05	Macrogenics, Inc.	FcgammaRIIB-specific antibodies and methods of use thereof
PT2495307T (pt)	2006-07-13	2018-05-10	Wyeth Llc	Produção do fator ix de coagulação com padrão melhorado de glicosilação
SG170032A1 (en)	2006-08-28	2011-04-29	Kyowa Hakko Kirin Co Ltd	Antagonistic human light-specific human monoclonal antibodies
WO2008044928A1 (en)	2006-10-10	2008-04-17	Academisch Ziekenhuis Bij De Universiteit Van Amsterdam	Complement inhibition for improved nerve regeneration
GB0621513D0 (en)	2006-10-30	2006-12-06	Domantis Ltd	Novel polypeptides and uses thereof
DK3276349T3 (da)	2006-11-01	2019-10-28	Ventana Med Syst Inc	Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåder til fremstilling og anvendelse deraf
WO2008055924A1 (en)	2006-11-07	2008-05-15	Vib Vzw	Diagnosis and treatment of t-cell acute lymphoblastic leukemia
EP2121743B1 (en)	2006-11-22	2015-06-03	Bristol-Myers Squibb Company	Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
CN101611056A (zh) *	2006-12-05	2009-12-23	埃博灵克斯股份有限公司	能够结合于血清蛋白的肽
KR20090088950A (ko)	2006-12-14	2009-08-20	쉐링 코포레이션	가공된 항-ｔｓｌｐ 항체
EP2557090A3 (en)	2006-12-19	2013-05-29	Ablynx N.V.	Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
WO2008074840A2 (en)	2006-12-19	2008-06-26	Ablynx N.V.	Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
US9023352B2 (en)	2007-02-20	2015-05-05	Tufts University	Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
AU2008219216A1 (en) *	2007-02-21	2008-08-28	Ablynx N.V.	Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
KR101520110B1 (ko)	2007-02-23	2015-05-18	머크 샤프 앤드 돔 코포레이션	가공된 항-ＩＬ-23ｐ19 항체
WO2008103473A1 (en)	2007-02-23	2008-08-28	Schering Corporation	Engineered anti-il-23p19 antibodies
EP2056838B1 (en)	2007-02-28	2013-09-25	Merck Sharp & Dohme Corp.	Combination therapy for treatment of immune disorders
MX2009009283A (es)	2007-02-28	2009-11-18	Schering Corp	Anticuerpos anti-interleuquina -23r de ingenieria.
DK2115126T3 (da) *	2007-03-02	2015-05-04	Wyeth Llc	Anvendelse af kobber og glutamat i cellekulturer til fremstilling af polypeptider
PT2308514E (pt)	2007-03-23	2013-09-06	To Bbb Holding B V	Conjugados para a administração orientada de medicamentos através da barreira hematoencefálica
TW200902708A (en)	2007-04-23	2009-01-16	Wyeth Corp	Methods of protein production using anti-senescence compounds
WO2008136694A1 (en)	2007-05-04	2008-11-13	Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa	Engineered rabbit antibody variable domains and uses thereof
CA2685222C (en)	2007-05-14	2017-12-19	Medimmune, Llc	Methods of reducing eosinophil levels
AU2008262489B2 (en) *	2007-05-23	2013-11-28	Ventana Medical Systems, Inc.	Polymeric carriers for immunohistochemistry and in situ hybridization
KR101886610B1 (ko)	2007-06-01	2018-08-09	오픈 모노클로날 테크놀로지, 인코포레이티드	내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
WO2008157299A2 (en) *	2007-06-15	2008-12-24	Wyeth	Differential expression profiling analysis of cell culture phenotypes and uses thereof
US10214588B2 (en)	2007-07-03	2019-02-26	Ablynx N.V.	Providing improved immunoglobulin sequences by mutating CDR and/or FR positions
AU2008276787B2 (en)	2007-07-13	2013-06-06	Bac Ip B.V.	Single-domain antigen-binding proteins that bind mammalian IgG
US20090017050A1 (en)	2007-07-13	2009-01-15	Ventana Medical Systems, Inc.	Egfr antigen-binding molecules and uses thereof
EP2188371B1 (en)	2007-08-09	2017-12-20	Wyeth LLC	Use of perfusion to enhance production of fed-batch cell culture in bioreactors
ES2667729T3 (es)	2007-09-26	2018-05-14	Ucb Biopharma Sprl	Fusiones de anticuerpos con doble especificidad
TWI489993B (zh)	2007-10-12	2015-07-01	Novartis Ag	骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
US8216571B2 (en)	2007-10-22	2012-07-10	Schering Corporation	Fully human anti-VEGF antibodies and methods of using
ES2663077T3 (es)	2007-11-02	2018-04-11	Novartis Ag	Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (lrp6)
JP5514399B2 (ja) *	2007-11-02	2014-06-04	国立大学法人岡山大学	無機硫黄化合物加水分解酵素の製造方法
EP2902495B1 (en)	2007-11-09	2019-12-25	The Salk Institute for Biological Studies	Use of tam receptor activators as immunosuppressors
WO2009068628A1 (en)	2007-11-27	2009-06-04	Ablynx N.V.	Constructs comprising single variable domains and an fc portion derived from lge.
US9308257B2 (en)	2007-11-28	2016-04-12	Medimmune, Llc	Protein formulation
WO2009086215A2 (en) *	2007-12-21	2009-07-09	Wyeth	Pathway analysis of cell culture phenotypes and uses thereof
AU2009212747B2 (en)	2008-01-31	2013-11-07	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Engineered antibody constant domain molecules
DE112009000507T5 (de)	2008-03-05	2011-02-10	Ablynx Nv	Neue Antigen-bindende Dimerkomplexe, Verfahren zu ihrer Herstellung und ihre Verwendung
EP2281005B1 (en)	2008-04-03	2013-11-20	Vib Vzw	Single domain antibodies capable of modulating bace1 activity
GB0809069D0 (en)	2008-05-19	2008-06-25	Univ Leuven Kath	Gene signatures
US9908943B2 (en)	2008-04-03	2018-03-06	Vib Vzw	Single domain antibodies capable of modulating BACE activity
JP2011516520A (ja)	2008-04-07	2011-05-26	アブリンクスエン．ヴェー．	Ｎｏｔｃｈ経路に指向性を有するアミノ酸配列及びその使用
CN102099377A (zh)	2008-04-11	2011-06-15	新兴产品开发西雅图有限公司	Cd37免疫治疗剂及其与双功能化学治疗剂的联合
WO2009127691A1 (en)	2008-04-17	2009-10-22	Ablynx N.V.	Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
PL2274331T3 (pl)	2008-05-02	2014-04-30	Novartis Ag	Ulepszone cząsteczki wiążące oparte na fibronektynie i ich zastosowanie
PE20091931A1 (es)	2008-05-22	2009-12-31	Bristol Myers Squibb Co	Proteinas de dominio de armazon basadas en fibronectina multivalentes
CA2720728C (en)	2008-06-05	2018-04-03	Ventana Medical Systems, Inc.	Compositions comprising nanomaterials and method for using such compositions for histochemical processes
GB2461546B (en) *	2008-07-02	2010-07-07	Argen X Bv	Antigen binding polypeptides
US8444976B2 (en)	2008-07-02	2013-05-21	Argen-X B.V.	Antigen binding polypeptides
CN105936648B (zh)	2008-07-18	2020-06-16	百时美施贵宝公司	Cd28结合为单价的组合物及使用方法
CA2731617A1 (en)	2008-07-22	2010-01-28	Maria Joao Saraiva	Amino acid sequences directed against multitarget scavenger receptors and polypeptides
HRP20150799T1 (hr)	2008-08-05	2015-09-11	Novartis Ag	Sastavi i postupci za protutijela protiv komplementnog proteina c5
WO2010033913A1 (en) *	2008-09-22	2010-03-25	Icb International, Inc.	Antibodies, analogs and uses thereof
US20100136584A1 (en) *	2008-09-22	2010-06-03	Icb International, Inc.	Methods for using antibodies and analogs thereof
JP2012504939A (ja)	2008-09-23	2012-03-01	ワイス・エルエルシー	架橋結合タンパク質による活性化シグナルの産生を予測するための方法
AU2009314311B2 (en)	2008-10-29	2013-01-10	Ablynx N.V.	Methods for purification of single domain antigen binding molecules
EP2362767B1 (en)	2008-10-29	2017-12-06	Ablynx N.V.	Formulations of single domain antigen binding molecules
CA2745218A1 (en)	2008-12-19	2010-06-24	Schering Corporation	Feed supplement for mammalian cell culture and methods of use
EP2370465B1 (en)	2008-12-19	2019-01-23	Ablynx N.V.	Genetic immunization for producing immunoglobulins against cell-associated antigens such as p2x7, cxcr7 or cxcr4
ES2701649T3 (es)	2009-01-14	2019-02-25	Ablynx Nv	Administración pulmonar de dominios variables individuales de inmunoglobulina y constructos de los mismos
US20100189919A1 (en) *	2009-01-27	2010-07-29	Xerox Corporation	Imaging System And Process Using Monoclonal Antibodies
EP2394159B1 (en)	2009-02-04	2018-09-26	Molecular Innovations	Assays for detecting prorenin, and antibodies used therein
EP2403873A1 (en)	2009-03-05	2012-01-11	Ablynx N.V.	Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
EP2230515B1 (en) *	2009-03-16	2014-12-17	Agilent Technologies, Inc.	Passivation of surfaces after ligand coupling
GB0905023D0 (en)	2009-03-24	2009-05-06	Univ Erasmus Medical Ct	Binding molecules
JP6159528B2 (ja)	2009-03-24	2017-07-05	ワイス・エルエルシー	高濃縮のタンパク質治療薬を生成するための膜蒸発
CA2758191C (en)	2009-04-10	2015-06-30	Ablynx N.V.	Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
AU2010230311B9 (en)	2009-04-27	2012-09-20	Novartis Ag	Composition and methods of use for therapeutic antibodies specific for the IL-12 receptore betal subunit
SI2424895T1 (en)	2009-04-27	2018-01-31	Novartis Ag	Ingredients and procedures for increasing muscle growth
US9464138B2 (en)	2009-04-30	2016-10-11	Ablynx N.V.	Method for the production of domain antibodies
WO2011019423A2 (en)	2009-05-20	2011-02-17	Schering Corporation	Modulation of pilr receptors to treat microbial infections
EP3205670A1 (en)	2009-06-05	2017-08-16	Ablynx N.V.	Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
KR101962476B1 (ko)	2009-07-03	2019-03-26	아비펩 피티와이 리미티트	면역성 접합체 및 그 제조방법
ES2804450T3 (es)	2009-07-10	2021-02-08	Ablynx Nv	Método para la producción de dominios variables
WO2011012646A2 (en)	2009-07-28	2011-02-03	F. Hoffmann-La Roche Ag	Non-invasive in vivo optical imaging method
EP2459594A1 (en)	2009-07-31	2012-06-06	N.V. Organon	Fully human antibodies to btla
US9133500B2 (en)	2009-08-10	2015-09-15	MorphoSys A6	Screening strategies for the identification of binders
PL2473528T3 (pl)	2009-09-03	2015-05-29	Ablynx Nv	Stabilne formulacje polipeptydów i ich zastosowanie
CA2810119C (en)	2009-09-03	2018-10-23	Cancer Research Technology Limited	Clec14a inhibitors
EP3023438B1 (en)	2009-09-03	2020-03-11	Merck Sharp & Dohme Corp.	Anti-gitr antibodies
WO2011029823A1 (en)	2009-09-09	2011-03-17	Novartis Ag	Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
GB201005063D0 (en)	2010-03-25	2010-05-12	Ucb Pharma Sa	Biological products
US20110172398A1 (en)	2009-10-02	2011-07-14	Boehringer Ingelheim International Gmbh	Bispecific binding molecules for anti-angiogenesis therapy
US20110195494A1 (en)	2009-10-02	2011-08-11	Boehringer Ingelheim International Gmbh	Dll4-binging molecules
EP2486056A1 (en)	2009-10-09	2012-08-15	Ablynx N.V.	Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
WO2011045079A1 (en)	2009-10-15	2011-04-21	Intercell Ag	Hepatitis b virus specific human antibodies
DK2491056T3 (da)	2009-10-22	2021-10-25	Univ Twente	Vhh til anvendelse i vævsreparation, organregenerering, organudskiftning og vævskonstruktion
WO2011050242A1 (en)	2009-10-23	2011-04-28	Millennium Pharmaceuticals, Inc.	Anti-gcc antibody molecules and related compositions and methods
WO2011051333A1 (en)	2009-10-30	2011-05-05	Novartis Ag	Universal fibronectin type iii bottom-side binding domain libraries
WO2011051327A2 (en)	2009-10-30	2011-05-05	Novartis Ag	Small antibody-like single chain proteins
WO2011051466A1 (en)	2009-11-02	2011-05-05	Novartis Ag	Anti-idiotypic fibronectin-based binding molecules and uses thereof
WO2011056772A1 (en)	2009-11-04	2011-05-12	Schering Corporation	Engineered anti-tslp antibody
US20120282276A1 (en)	2009-11-05	2012-11-08	The Regents Of The University Of Michigan	Biomarkers predictive of progression of fibrosis
US9644022B2 (en)	2009-11-30	2017-05-09	Ablynx N.V.	Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
CN104131035A (zh) *	2009-12-10	2014-11-05	瑞泽恩制药公司	生产重链抗体的小鼠
US20110150885A1 (en)	2009-12-11	2011-06-23	Atyr Pharma, Inc.	Aminoacyl trna synthetases for modulating hematopoiesis
EP3309176B1 (en)	2009-12-14	2025-10-01	Ablynx N.V.	Immunoglobulin single variable domain antibodies against ox40l, constructs and their therapeutic use
US8691227B2 (en)	2009-12-17	2014-04-08	Merck Sharp & Dohme Corp.	Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
AU2010336029B2 (en)	2009-12-23	2011-10-13	Avipep Pty Ltd	Immuno-conjugates and methods for producing them 2
WO2011083141A2 (en)	2010-01-08	2011-07-14	Ablynx Nv	Method for generation of immunoglobulin sequences by using lipoprotein particles
AR079944A1 (es)	2010-01-20	2012-02-29	Boehringer Ingelheim Int	Anticuerpo neutralizante de la actividad de un anticoagulante
JP2013518853A (ja)	2010-02-05	2013-05-23	アブリンクスエン．ヴェー．	血清アルブミンと結合することが可能なペプチド並びにこれを含む化合物、構築物及びポリペプチド
US9120855B2 (en)	2010-02-10	2015-09-01	Novartis Ag	Biologic compounds directed against death receptor 5
JP2013519869A (ja)	2010-02-10	2013-05-30	ノバルティスアーゲー	筋肉成長のための方法および化合物
PL2533761T3 (pl)	2010-02-11	2019-09-30	Ablynx N.V.	Sposoby i kompozycje do wytwarzania aerozoli
WO2011098518A2 (en)	2010-02-11	2011-08-18	Ablynx Nv	Delivery of immunoglobulin variable domains and constructs thereof
AU2011220578B2 (en)	2010-02-26	2014-09-25	Ventana Medical Systems, Inc.	Polytag probes
EA201201227A1 (ru)	2010-03-03	2013-04-30	Бёрингер Ингельхайм Интернациональ Гмбх	Бипаратопные а-бета-связывающие полипептиды
WO2011117423A1 (en)	2010-03-26	2011-09-29	Ablynx N.V.	Immunoglobulin single variable domains directed against cxcr7
US20130041349A1 (en)	2010-03-26	2013-02-14	Westfaelische Wilhelms-Universitaet Muenster	Substitute therapy for glucocorticoids
US9101674B2 (en)	2010-03-29	2015-08-11	Vib Vzw	Targeting and in vivo imaging of tumor-associated macrophages
US9556273B2 (en)	2010-03-29	2017-01-31	Vib Vzw	Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
EP2555614B1 (en)	2010-04-06	2018-11-14	Agrosavfe N.V.	Specific delivery of agrochemicals
GB201105584D0 (en)	2011-04-01	2011-05-18	Imp Innovations Ltd	Cancer methods
JP5822913B2 (ja)	2010-04-20	2015-11-25	ヴェンタナメディカルシステムズ，インク．	２色発色性インサイツハイブリダイゼーション
WO2011139714A2 (en)	2010-04-26	2011-11-10	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
AU2011248614B2 (en)	2010-04-27	2017-02-16	Pangu Biopharma Limited	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
EP2563911B1 (en)	2010-04-28	2021-07-21	aTyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
US9068177B2 (en)	2010-04-29	2015-06-30	Atyr Pharma, Inc	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
CN103097523B (zh)	2010-04-29	2016-09-28	Atyr医药公司	与天冬酰胺酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
EP2563383B1 (en)	2010-04-29	2017-03-01	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
PT2563813E (pt)	2010-04-30	2015-11-26	Alexion Pharma Inc	Anticorpos anti-c5a e métodos para utilização dos anticorpos
AU2011248230B2 (en)	2010-05-03	2016-10-06	Pangu Biopharma Limited	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetases
US9034321B2 (en)	2010-05-03	2015-05-19	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
US8961961B2 (en)	2010-05-03	2015-02-24	a Tyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases
AU2011248101B2 (en)	2010-05-04	2016-10-20	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex
ES2596431T3 (es)	2010-05-04	2017-01-09	The Brigham And Women's Hospital, Inc.	Antagonista de cadherina-11 para el tratamiento de fibrosis
US8877188B2 (en)	2010-05-04	2014-11-04	The Brigham And Women's Hospital, Inc.	Detection and treatment of non-dermal fibrosis
ES2949159T3 (es)	2010-05-06	2023-09-26	Novartis Ag	Composiciones y métodos de uso para anticuerpos terapéuticos de proteína 6 relacionada con lipoproteínas de baja densidad (LRP6)
AU2011249782B2 (en)	2010-05-06	2014-10-02	Novartis Ag	Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (LRP6) multivalent antibodies
BR112012028006A2 (pt)	2010-05-07	2016-08-02	Hoffmann La Roche	método de imuno-histoquímica (ihq), uso de um domínio de ligação, kit e domínio de ligação terapeuticamente ativo
JP6396656B2 (ja)	2010-05-14	2018-09-26	エータイアーファーマ，インコーポレイテッド	フェニルアラニルβｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
NZ603570A (en)	2010-05-20	2014-12-24	Ablynx Nv	Biological materials related to her3
EA201291328A1 (ru)	2010-06-22	2013-10-30	Дзе Риджентс Оф Дзе Юниверсити Оф Колорадо, Э Боди Корпорейт	АНТИТЕЛА К ФРАГМЕНТУ C3d КОМПОНЕНТА КОМПЛЕМЕНТА 3
WO2011161263A1 (en)	2010-06-25	2011-12-29	Ablynx Nv	Pharmaceutical compositions for cutaneous administration
EP2588443A2 (en)	2010-07-02	2013-05-08	Ventana Medical Systems, Inc.	Hapten conjugates for target detection
CA2805548A1 (en)	2010-07-02	2012-01-05	Vib Vzw	The role of fragile x mental retardation gene and protein in cancer metastasis
EP2593125B1 (en)	2010-07-12	2017-11-01	aTyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
EP2593476A2 (en)	2010-07-16	2013-05-22	Ablynx N.V.	Modified single domain antigen binding molecules and uses thereof
GB201014715D0 (en)	2010-09-06	2010-10-20	Vib Vzw	Nanobodies stabilizing functional conformational states of GPCRS
GB201012845D0 (en)	2010-07-30	2010-09-15	Vib Vzw	Inhibition of dicer function for treatment of cancer
RU2612903C2 (ru)	2010-08-02	2017-03-13	Ридженерон Фармасьютикалз, Инк.	Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены
WO2012024185A1 (en)	2010-08-16	2012-02-23	Ventana Medical Systems, Inc.	Substrates for chromogenic detection and methods of use in detection assays and kits
BR112013004012B1 (pt)	2010-08-20	2021-03-23	Novartis Ag	Anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo ao receptor her3, seu uso e composição farmacêutica
CA2807607A1 (en)	2010-08-20	2012-02-23	Wyeth Llc	Cell culture of growth factor-free adapted cells
CA2808539C (en)	2010-08-25	2021-05-25	Atyr Pharma, Inc.	Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases
EP2609116A1 (en)	2010-08-26	2013-07-03	Agrosavfe N.V.	Insect binding antibodies
EP2609115B1 (en)	2010-08-26	2017-05-31	Agrosavfe N.V.	Compositions for seed treatment
US20120225081A1 (en)	2010-09-03	2012-09-06	Boehringer Ingelheim International Gmbh	Vegf-binding molecules
US20120244141A1 (en)	2010-09-28	2012-09-27	Boehringer Ingelheim International Gmbh	Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
EP2621953B1 (en)	2010-09-30	2017-04-05	Ablynx N.V.	Biological materials related to c-met
EP2625203A1 (en)	2010-10-05	2013-08-14	Novartis AG	Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
DK3279214T3 (da)	2010-10-29	2024-12-09	Ablynx Nv	Fremgangsmåde til fremstilling af variable immunglobulin-enkeltdomæner
GB201018602D0 (en)	2010-11-04	2010-12-22	Vib Vzw	MMP8 inactivating antigen binding proteins
KR101931936B1 (ko)	2010-11-05	2018-12-26	에이자이 아이엔씨.	엽산 수용체 알파-발현 암에 대한 진단 및 예후 마커로서의 엽산 수용체 알파
NZ610075A (en)	2010-11-08	2015-03-27	Novartis Ag	Cxcr2 binding polypeptides
WO2012084895A2 (en)	2010-12-20	2012-06-28	Universiteit Gent	Crystal structure of flt3 ligand-receptor complex
EP2658869B1 (en)	2010-12-30	2019-06-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antigen binding formats for use in therapeutic treatments or diagnostic assays
EP2659000B1 (en)	2010-12-30	2016-08-10	Ventana Medical Systems, Inc.	Enhanced deposition of chromogens utilizing pyrimidine analogs
EP3763740A1 (en)	2011-01-26	2021-01-13	Celldex Therapeutics, Inc.	Anti-kit antibodies and uses thereof
US9850315B2 (en)	2011-02-01	2017-12-26	Bac Ip B.V.	Antigen-binding protein directed against epitope in the CH1 domain of human IgG antibodies
AR085141A1 (es)	2011-02-03	2013-09-11	Alexion Pharma Inc	Un metodo para prolongar la supervivencia de un aloinjerto renal, uso de un anticuerpo anti-cd200 para prolongar la supervivencia de aloinjertos
WO2012119999A1 (en)	2011-03-07	2012-09-13	F. Hoffmann-La Roche Ag	Means and methods for in vivo testing of therapeutic antibodies
EP2683413A1 (en)	2011-03-07	2014-01-15	F.Hoffmann-La Roche Ag	In vivo selection of therapeutically active antibodies
AU2012228424B2 (en)	2011-03-14	2015-05-07	Ventana Medical Systems, Inc.	A method of analyzing chromosomal translocations and a system therefore
EP2686016B1 (en)	2011-03-14	2019-05-01	Cellmid Limited	Antibody recognizing n-domain of midkine
US20150158948A9 (en)	2011-03-28	2015-06-11	Francis Descamps	Bispecific anti-cxcr7 immunoglobulin single variable domains
ES2688591T3 (es)	2011-03-28	2018-11-05	Ablynx N.V.	Método para producir formulaciones sólidas que comprenden dominios variables individuales de inmunoglobulina
JP6130350B2 (ja)	2011-03-30	2017-05-17	アブリンクスエン．ヴェー．	ＴＮＦαに対する単一ドメイン抗体で免疫障害を処置する方法
CA2827787A1 (en)	2011-03-30	2012-10-04	Boehringer Ingelheim International Gmbh	Anticoagulant antidotes
RS57492B1 (sr)	2011-03-31	2018-10-31	Merck Sharp & Dohme	Stabilne formulacije antitela za humani receptor programirane smrti pd-1 i srodni tretmani
US20130078247A1 (en)	2011-04-01	2013-03-28	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to dii4 and ang2
US9527925B2 (en)	2011-04-01	2016-12-27	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to VEGF and ANG2
MX338353B (es)	2011-04-20	2016-04-13	Medimmune Llc	Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1.
UA117218C2 (uk)	2011-05-05	2018-07-10	Мерк Патент Гмбх	Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP2707382B1 (en)	2011-05-09	2019-07-17	Ablynx NV	Method for the production of immunoglobulin single variable domains
CN107903325B (zh)	2011-05-16	2021-10-29	埃泰美德(香港)有限公司	多特异性fab融合蛋白及其使用方法
KR102072250B1 (ko)	2011-05-27	2020-03-02	아블린쓰 엔.브이.	Ｒａｎｋｌ 결합 펩티드를 이용한 골 재흡수 억제
US9580480B2 (en)	2011-05-31	2017-02-28	Massachusetts Institute Of Technology	Cell-directed synthesis of multifunctional nanopatterns and nanomaterials
AU2012269720B2 (en)	2011-06-13	2015-01-22	Csl Limited	Antibodies against G-CSFR and uses thereof
WO2012172495A1 (en)	2011-06-14	2012-12-20	Novartis Ag	Compositions and methods for antibodies targeting tem8
CA2839834A1 (en)	2011-06-21	2012-12-27	Vib Vzw	Binding domains directed against gpcr:g protein complexes and uses derived thereof
WO2012175740A1 (en)	2011-06-23	2012-12-27	Ablynx Nv	Immunoglobulin single variable domains directed against ige
LT2723771T (lt)	2011-06-23	2019-12-10	Ablynx Nv	Serumo albuminą surišantys baltymai
DK2726099T3 (da)	2011-07-01	2018-11-05	Novartis Ag	Fremgangsmåde til behandling af metaboliske lidelser
GB201112056D0 (en)	2011-07-14	2011-08-31	Univ Leuven Kath	Antibodies
WO2013010955A1 (en)	2011-07-15	2013-01-24	Morphosys Ag	Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
UY34254A (es)	2011-08-17	2013-04-05	Glaxo Group Ltd	Proteínas y péptidos modificados.
WO2013033073A1 (en)	2011-08-31	2013-03-07	Ventana Medical Systems, Inc.	Expression of ets related gene (erg) and phosphatase and tensin homolog (pten) correlates with prostate cancer capsular penetration
GB201115529D0 (en)	2011-09-08	2011-10-26	Imp Innovations Ltd	Antibodies, uses and methods
WO2013036130A1 (en)	2011-09-09	2013-03-14	Universiteit Utrecht Holding B.V.	Broadly neutralizing vhh against hiv-1
BR112014006394A2 (pt)	2011-09-19	2017-03-28	Kymab Ltd	manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
WO2013041901A1 (en)	2011-09-20	2013-03-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for preparing single domain antibody microarrays
AU2012311443B2 (en)	2011-09-23	2016-12-01	Ablynx Nv	Prolonged inhibition of interleukin-6 mediated signaling
EP2761008A1 (en)	2011-09-26	2014-08-06	Kymab Limited	Chimaeric surrogate light chains (slc) comprising human vpreb
CN103889451B (zh)	2011-09-30	2016-06-29	埃博灵克斯股份有限公司	与C-Met相关的生物物质
US20130085139A1 (en)	2011-10-04	2013-04-04	Royal Holloway And Bedford New College	Oligomers
WO2013054307A2 (en)	2011-10-14	2013-04-18	Novartis Ag	Antibodies and methods for wnt pathway-related diseases
US9127056B2 (en)	2011-10-17	2015-09-08	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Monospecific and bispecific human monoclonal antibodies targeting insulin-like growth factor II (IGF-II)
US9265817B2 (en)	2011-10-28	2016-02-23	Patrys Limited	PAT-LM1 epitopes and methods for using same
GB2496375A (en)	2011-10-28	2013-05-15	Kymab Ltd	A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
ES2649098T3 (es)	2011-11-11	2018-01-10	Ucb Biopharma Sprl	Anticuerpos de unión a albumina y fragmentos de unión de los mismos
WO2013079606A1 (en)	2011-12-01	2013-06-06	Ventana Medical Systems, Inc.	Automated dual stain of mirna and protein targets
WO2013079973A1 (en)	2011-12-02	2013-06-06	Di Cara Danielle Marie	Antibodies against hgf - receptor and uses
GB201122047D0 (en)	2011-12-21	2012-02-01	Kymab Ltd	Transgenic animals
EA201491107A1 (ru)	2011-12-05	2014-11-28	Новартис Аг	Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен ii her3
WO2013084147A2 (en)	2011-12-05	2013-06-13	Novartis Ag	Antibodies for epidermal growth factor receptor 3 (her3)
SG11201403416TA (en)	2011-12-21	2014-07-30	Novartis Ag	Compositions and methods for antibodies targeting factor p
US10112987B2 (en)	2012-01-09	2018-10-30	Icb International, Inc.	Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US10112988B2 (en)	2012-01-09	2018-10-30	Icb International, Inc.	Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
WO2013108126A2 (en)	2012-01-16	2013-07-25	University Of Oslo	Methyltransferases and uses thereof
LT2804878T (lt)	2012-01-20	2018-12-10	Genzyme Corporation	Anti-cxcr3 antikūnai
WO2013113696A1 (en)	2012-01-30	2013-08-08	Vib Vzw	Means and method for diagnosis and treatment of alzheimer's disease
WO2013121042A1 (en)	2012-02-16	2013-08-22	Vib Vzw	PP2A SUBUNITS IN DNA REPAIR, THE PP2A B55α SUBUNIT AS NOVEL PHD2 INTERACTING PROTEIN, AND IMPLICATIONS FOR CANCER
MX349192B (es)	2012-02-27	2017-07-18	Boehringer Ingelheim Int	Polipeptidos de union a cx3cr1.
US9592289B2 (en)	2012-03-26	2017-03-14	Sanofi	Stable IgG4 based binding agent formulations
US10041950B2 (en)	2012-03-27	2018-08-07	Ventana Medical Systems, Inc.	Signaling conjugates and methods of use
SI2831111T1 (sl)	2012-03-30	2019-06-28	Boehringer Ingelheim International Gmbh	Ang2-vezavne molekule
US9156915B2 (en)	2012-04-26	2015-10-13	Thomas Jefferson University	Anti-GCC antibody molecules
US9328174B2 (en)	2012-05-09	2016-05-03	Novartis Ag	Chemokine receptor binding polypeptides
AU2013265665B2 (en)	2012-05-24	2017-10-26	Vib Vzw	Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
EP2687595B1 (en)	2012-07-19	2018-05-30	Laboratoire Français du Fractionnement et des Biotechnologies	Method for purifying transgenic factor VII
WO2014018535A1 (en)	2012-07-25	2014-01-30	Salk Institute For Biological Studies	Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidylserine
RU2681730C2 (ru)	2012-07-25	2019-03-12	Селлдекс Терапьютикс Инк.	Антитела против kit и их применения
US9605074B2 (en)	2012-08-30	2017-03-28	The General Hospital Corporation	Multifunctional nanobodies for treating cancer
UA118441C2 (uk)	2012-10-08	2019-01-25	Протена Біосаєнсиз Лімітед	Антитіло, що розпізнає альфа-синуклеїн
EP3750560A3 (en)	2012-10-09	2021-03-24	Biogen MA Inc.	Combination therapies and uses for treatment of demyelinating disorders
US9663797B2 (en)	2012-11-20	2017-05-30	Novartis Ag	Optimized expression cassette for expressing a polypeptide with high yield
WO2014084859A1 (en)	2012-11-30	2014-06-05	Novartis Ag	Molecules and methods for modulating tmem16a activities
AP2015008365A0 (en)	2012-12-05	2015-04-30	Novartis Ag	Compositions and methods for antibodies targeting epo
WO2014087010A1 (en)	2012-12-07	2014-06-12	Ablynx N.V.	IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
FI3653049T3 (fi)	2012-12-14	2023-11-02	Omniab Inc	Polynukleotidit, jotka koodaavat jyrsijän vasta-aineita, joissa on ihmisen idiotyyppejä, ja näitä käsittävät eläimet
WO2014099997A1 (en)	2012-12-18	2014-06-26	Novartis Ag	Compositions and methods that utilize a peptide tag that binds to hyaluronan
SG11201504764SA (en)	2012-12-19	2015-07-30	Amplimmune Inc	Anti-human b7-h4 antibodies and their uses
AU2013204922B2 (en)	2012-12-20	2015-05-14	Celgene Corporation	Chimeric antigen receptors
AR093984A1 (es)	2012-12-21	2015-07-01	Merck Sharp & Dohme	Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
EP2935332B1 (en)	2012-12-21	2021-11-10	MedImmune, LLC	Anti-h7cr antibodies
EP2951201B1 (en)	2013-01-30	2017-10-18	VIB vzw	Novel chimeric polypeptides for screening and drug discovery purposes
WO2014120916A1 (en)	2013-02-01	2014-08-07	Bristol-Myers Squibb Company	Pegylated domain antibodies monovalent for cd28 binding and methods of use
CA2900147C (en)	2013-02-05	2023-09-05	Vib Vzw	Muscarinic acetylcholine receptor binding agents and uses thereof
CN110551217B (zh)	2013-02-07	2023-12-15	Csl有限公司	Il-11r结合蛋白及其应用
ES2758473T3 (es)	2013-02-08	2020-05-05	Novartis Ag	Anticuerpos anti-IL-17A y su uso en el tratamiento de trastornos autoinmunitarios e inflamatorios
MX2015010350A (es)	2013-02-26	2015-10-29	Roche Glycart Ag	Moleculas de union a antigeno biespecificas que activan la celula t.
JP6416793B2 (ja)	2013-02-28	2018-10-31	カプリオンプロテオミクスインコーポレーテッド	結核のバイオマーカー及びその使用
EP3764084A1 (en)	2013-03-12	2021-01-13	Ventana Medical Systems, Inc.	Digitally enhanced microscopy for multiplexed histology
EA035943B1 (ru)	2013-03-13	2020-09-03	Протена Биосайенсес Лимитед	Антитело, связывающееся с тау-белком человека
EP2970479B1 (en)	2013-03-14	2019-04-24	Novartis AG	Antibodies against notch 3
EP3623380B1 (en)	2013-03-15	2025-10-22	Novartis AG	Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
JP6493692B2 (ja)	2013-03-15	2019-04-10	セルジーンコーポレイション	修飾されたｔリンパ球
AU2014229952B2 (en)	2013-03-15	2018-10-04	Vib Vzw	Anti-macrophage mannose receptor single variable domains for use in cardiovascular diseases
WO2014141192A1 (en)	2013-03-15	2014-09-18	Erasmus University Medical Center	Generation of heavy chain-only antibodies
WO2014144292A2 (en)	2013-03-15	2014-09-18	Sanofi Pasteur Biologics , Llc	Antibodies against clostridium difficile toxins and methods of using the same
WO2014146575A1 (en)	2013-03-19	2014-09-25	Beijing Shenogen Pharma Group Ltd.	Antibodies and methods for treating estrogen receptor-associated diseases
CN105358698B (zh)	2013-04-29	2024-02-20	生物催化公司	包含结合至鞘脂的抗体的农用化学组合物
EP2994163B1 (en)	2013-05-09	2019-08-28	The United States of America, as represented by The Secretary, Department of Health and Human Services	Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use
NL1040254C2 (en)	2013-05-17	2014-11-24	Ablynx Nv	Stable formulations of immunoglobulin single variable domains and uses thereof.
US10316092B2 (en)	2013-05-24	2019-06-11	The John Hopkins University	Anti-B7-H5 antibodies and their uses
WO2014194293A1 (en)	2013-05-30	2014-12-04	Amplimmune, Inc.	Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
WO2014197849A2 (en)	2013-06-06	2014-12-11	Igenica Biotherapeutics, Inc.	Anti-c10orf54 antibodies and uses thereof
US9562101B2 (en)	2013-06-21	2017-02-07	Novartis Ag	Lectin-like oxidized LDL receptor 1 antibodies and methods of use
AR096601A1 (es)	2013-06-21	2016-01-20	Novartis Ag	Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
WO2014207173A1 (en)	2013-06-27	2014-12-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Interleukin 15 (il-15) antagonists and uses thereof for the treatment of autoimmune diseases and inflammatory diseases
WO2015001082A1 (en)	2013-07-05	2015-01-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof
US9951131B2 (en)	2013-07-12	2018-04-24	Prothena Biosciences Limited	Antibodies that recognize IAPP
WO2015004632A1 (en)	2013-07-12	2015-01-15	Neotope Biosciences Limited	Antibodies that recognize iapp
JP6211701B2 (ja)	2013-08-07	2017-10-11	アレクシオンファーマシューティカルズ，インコーポレイテッド	非典型溶血性尿毒症症候群のバイオマーカータンパク質
US20160200818A1 (en)	2013-08-14	2016-07-14	Novartis Ag	Methods of treating Sporadic Inclusion Body Myositis
AR097306A1 (es)	2013-08-20	2016-03-02	Merck Sharp & Dohme	Modulación de la inmunidad tumoral
EP3530286A1 (en)	2013-11-28	2019-08-28	CSL Limited	Method of treating diabetic nephropathy
EP2883883A1 (en)	2013-12-16	2015-06-17	Cardio3 Biosciences S.A.	Therapeutic targets and agents useful in treating ischemia reperfusion injury
ES2851386T3 (es)	2013-12-18	2021-09-06	Csl Ltd	Método de tratamiento de las heridas
EP3083964B1 (en)	2013-12-19	2022-01-26	Novartis AG	Human mesothelin chimeric antigen receptors and uses thereof
US10287354B2 (en)	2013-12-20	2019-05-14	Novartis Ag	Regulatable chimeric antigen receptor
BR112016014284A2 (pt)	2013-12-20	2017-12-05	Intervet Int Bv	anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo
WO2015100409A2 (en)	2013-12-26	2015-07-02	Tufts University	Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
JP6687525B2 (ja)	2014-01-30	2020-04-22	ブイアイビーブイゼットダブリュＶｉｂＶｚｗ	オピオイド受容体結合剤およびその使用
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
JP6764348B2 (ja)	2014-02-11	2020-09-30	ビステラ，インコーポレイテッド	デングウイルスに対する抗体分子およびその使用
US10675352B2 (en)	2014-02-14	2020-06-09	Centrose, Llc	Extracellular targeted drug conjugates
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
NZ711451A (en)	2014-03-07	2016-05-27	Alexion Pharma Inc	Anti-c5 antibodies having improved pharmacokinetics
KR20220126813A (ko)	2014-03-14	2022-09-16	노파르티스 아게	Lag-3에 대한 항체 분자 및 그의 용도
US20170335281A1 (en)	2014-03-15	2017-11-23	Novartis Ag	Treatment of cancer using chimeric antigen receptor
ES2857226T3 (es)	2014-03-15	2021-09-28	Novartis Ag	Receptor de antígeno quimérico regulable
JP2017510273A (ja)	2014-03-21	2017-04-13	リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	異なる結合特性を示すｖｌ抗原結合タンパク質
CN106255410B (zh)	2014-03-21	2020-01-10	瑞泽恩制药公司	产生单结构域结合蛋白的非人动物
JP6744856B2 (ja)	2014-04-08	2020-08-19	プロセナ・バイオサイエンシズ・リミテッド	α−シヌクレインを認識する抗体を含む血液脳関門シャトル
TW201622746A (zh)	2014-04-24	2016-07-01	諾華公司	改善或加速髖部骨折術後身體復原之方法
MX370018B (es)	2014-04-25	2019-11-28	Bluebird Bio Inc	Metodos mejorados para la elaboracion de terapias celulares adoptivas.
LT3134432T (lt)	2014-04-25	2020-04-10	Bluebird Bio, Inc.	Mnd promotorius chimerinių antigenų receptoriams
US9388239B2 (en)	2014-05-01	2016-07-12	Consejo Nacional De Investigation Cientifica	Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
EP3702369A1 (en)	2014-05-16	2020-09-02	Ablynx NV	Immunoglobulin variable domains
PL3148579T3 (pl)	2014-05-28	2021-07-19	Agenus Inc.	Przeciwciała anty-gitr i sposoby ich zastosowania
LT3151672T (lt)	2014-06-06	2021-02-10	Bluebird Bio, Inc.	Patobulintos t ląstelių kompozicijos
NL2013007B1 (en)	2014-06-16	2016-07-05	Ablynx Nv	Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
NL2013661B1 (en)	2014-10-21	2016-10-05	Ablynx Nv	KV1.3 Binding immunoglobulins.
US20170291939A1 (en)	2014-06-25	2017-10-12	Novartis Ag	Antibodies specific for il-17a fused to hyaluronan binding peptide tags
EP3160991A2 (en)	2014-06-25	2017-05-03	Novartis AG	Compositions and methods for long acting proteins
US20170290876A1 (en)	2014-06-25	2017-10-12	Novartis Ag	Compositions and methods for long acting proteins
SG10201913765YA (en)	2014-07-21	2020-03-30	Novartis Ag	Treatment of cancer using a cd33 chimeric antigen receptor
WO2016014565A2 (en)	2014-07-21	2016-01-28	Novartis Ag	Treatment of cancer using humanized anti-bcma chimeric antigen receptor
WO2016014530A1 (en)	2014-07-21	2016-01-28	Novartis Ag	Combinations of low, immune enhancing. doses of mtor inhibitors and cars
US11542488B2 (en)	2014-07-21	2023-01-03	Novartis Ag	Sortase synthesized chimeric antigen receptors
PT3194976T (pt)	2014-07-22	2020-07-03	Univ Brussel Vrije	Métodos para selecionar agentes que estabilizam complexos proteicos
US20170226216A1 (en)	2014-07-24	2017-08-10	Bluebird Bio, Inc.	Bcma chimeric antigen receptors
US20180036442A1 (en)	2014-07-29	2018-02-08	Vrije Universiteit Brussel	Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
CA2954359C (en)	2014-07-29	2018-09-25	Vrije Universiteit Brussel	Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer
EP4205749A1 (en)	2014-07-31	2023-07-05	Novartis AG	Subset-optimized chimeric antigen receptor-containing cells
TW201613977A (en)	2014-08-07	2016-04-16	Novartis Ag	Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
TWI675043B (zh)	2014-08-07	2019-10-21	瑞士商諾華公司	血管生成素樣４抗體及其使用方法
US10851149B2 (en)	2014-08-14	2020-12-01	The Trustees Of The University Of Pennsylvania	Treatment of cancer using GFR α-4 chimeric antigen receptor
JO3663B1 (ar)	2014-08-19	2020-08-27	Merck Sharp & Dohme	الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
DK3183268T3 (da)	2014-08-19	2020-05-11	Univ Pennsylvania	Behandling af cancer ved anvendelse af en cd123-kimær antigenreceptor
MX389684B (es)	2014-08-19	2025-03-20	Merck Sharp & Dohme Llc	Anticuerpos anti tigit.
EP3925622A1 (en)	2014-09-13	2021-12-22	Novartis AG	Combination therapies
MX2017003645A (es)	2014-09-17	2017-05-30	Novartis Ag	Direccion de celulas citotoxicas con receptores quimericos para inmunoterapia adoptiva.
AU2015327928A1 (en)	2014-10-03	2017-05-04	Nanotics, Llc	Compositions and methods for inhibiting the biological activity of soluble biomolecules
JP2017535528A (ja)	2014-10-03	2017-11-30	ノバルティスアーゲー	組み合わせ治療
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
JP2017538779A (ja)	2014-10-10	2017-12-28	アブリンクス・エヌ・フェー	Ｒｓｖ感染の治療方法
CN106999420B (zh)	2014-10-10	2021-08-10	埃博灵克斯股份有限公司	用于呼吸系统疾病的气溶胶疗法的吸入装置
EP3206711B1 (en)	2014-10-14	2023-05-31	Novartis AG	Antibody molecules to pd-l1 and uses thereof
US10584175B2 (en)	2014-10-23	2020-03-10	La Trobe University	FN14-binding proteins and uses thereof
AR102550A1 (es)	2014-11-05	2017-03-08	Agrosavfe Nv	Planta transgénica que comprende un polinucleótido que codifica un dominio variable de anticuerpo de cadena pesada
WO2016090034A2 (en)	2014-12-03	2016-06-09	Novartis Ag	Methods for b cell preconditioning in car therapy
US11001625B2 (en)	2014-12-10	2021-05-11	Tufts University	VHH based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
RS61249B1 (sr)	2014-12-11	2021-01-29	Pf Medicament	Antitela na c10orf54 i njihova upotreba
CN112358551B (zh)	2014-12-12	2024-02-02	2赛文缇生物公司	Bcma嵌合抗原受体
WO2016094834A2 (en)	2014-12-12	2016-06-16	Alexion Pharmaceuticals, Inc.	A method for treating a complement mediated disorder caused by an infectious agent in a patient
US10940212B2 (en)	2014-12-19	2021-03-09	Monash University	IL-21 agonist antibodies and methods of treatment using same
UY36449A (es)	2014-12-19	2016-07-29	Novartis Ag	Composiciones y métodos para anticuerpos dirigidos a bmp6
US20170340733A1 (en)	2014-12-19	2017-11-30	Novartis Ag	Combination therapies
ES2772348T3 (es)	2014-12-19	2020-07-07	Ablynx Nv	Dímeros de Nanobody con uniones cisteína
ES2862701T3 (es)	2014-12-22	2021-10-07	Univ Rockefeller	Anticuerpos agonistas anti-MERTK y usos de los mismos
IL253149B2 (en)	2014-12-29	2023-11-01	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
MX391051B (es)	2014-12-30	2025-03-21	Celgene Corp	Anticuerpos anti-cd47 y usos de los mismos.
JP6885867B2 (ja)	2014-12-31	2021-06-16	チェックメイトファーマシューティカルズ，インコーポレイテッド	組合せ腫瘍免疫療法
HK1246810A1 (zh)	2015-01-08	2018-09-14	Biogen Ma Inc.	Lingo-1对抗药及用於治疗脱髓鞘疾病的用途
GB201501004D0 (en)	2015-01-21	2015-03-04	Cancer Rec Tech Ltd	Inhibitors
WO2016126608A1 (en)	2015-02-02	2016-08-11	Novartis Ag	Car-expressing cells against multiple tumor antigens and uses thereof
WO2016124568A1 (en)	2015-02-03	2016-08-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anti-rho gtpase conformational single domain antibodies and uses thereof
EP3254110B1 (en)	2015-02-03	2020-03-18	Ventana Medical Systems, Inc.	Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1)
WO2016128549A1 (en)	2015-02-13	2016-08-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Polypeptides for engineering integrase chimeric proteins and their use in gene therapy
KR20170140180A (ko)	2015-02-24	2017-12-20	더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈	중동 호흡기 증후군 코로나 바이러스 면역원, 항체 및 그 용도
WO2016135041A1 (en)	2015-02-26	2016-09-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Fusion proteins and antibodies comprising thereof for promoting apoptosis
EP3061826A1 (en)	2015-02-27	2016-08-31	Novartis AG	Flavivirus replicons
CN108064169B (zh)	2015-03-03	2022-02-11	科马布有限公司	抗体、用途和方法
ES2929614T3 (es)	2015-03-17	2022-11-30	Memorial Sloan Kettering Cancer Center	Anticuerpos anti-MUC16 y usos de los mismos
MA41795A (fr)	2015-03-18	2018-01-23	Sarepta Therapeutics Inc	Exclusion d'un exon induite par des composés antisens dans la myostatine
JP2018508224A (ja)	2015-03-19	2018-03-29	リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	抗原を結合する軽鎖可変領域を選択する非ヒト動物
TR201904903T4 (tr)	2015-03-25	2019-05-21	Alexion Pharma Inc	Alternatif tamamlama yolağının C3 ve C5 konvertazının proteaz aktivitesinin ölçülmesine yönelik bir yöntem.
EP3274724A1 (en)	2015-03-25	2018-01-31	Alexion Pharmaceuticals, Inc.	A method for measuring the protease activity of factor d of the alternative complement pathway
JP6895421B2 (ja)	2015-03-31	2021-06-30	ブイエイチスクエアードリミテッド	ポリペプチド
JP2018511346A (ja)	2015-03-31	2018-04-26	ブイエイチスクエアードリミテッド	ポリペプチド
CN107427577A (zh)	2015-03-31	2017-12-01	韦斯夸尔德有限公司	具有蛋白酶可切割接头的肽构建体
ES3029413T3 (en)	2015-04-02	2025-06-24	Ablynx Nv	Bispecific cxcr4-cd-4 polypeptides with potent anti-hiv activity
CN107683291B (zh)	2015-04-02	2021-11-19	英特维特国际股份有限公司	针对犬白介素-4受体α的抗体
ES2876974T3 (es)	2015-04-07	2021-11-15	Novartis Ag	Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
WO2016166110A1 (en)	2015-04-13	2016-10-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treatment of haemorrhagic diseases
US9778265B2 (en)	2015-04-16	2017-10-03	The United States Of America, As Represented By The Secretary Of The Navy	Charged peptide appendage to facilitate oriented protein covalent immobilization
EP3283529B1 (en)	2015-04-17	2023-06-07	The General Hospital Corporation	Agents, systems and methods for treating cancer
CN108473957B (zh)	2015-04-17	2024-07-16	诺华股份有限公司	改善嵌合抗原受体表达细胞的功效和扩增的方法
US12128069B2 (en)	2015-04-23	2024-10-29	The Trustees Of The University Of Pennsylvania	Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
BR112017023849A2 (pt)	2015-05-07	2018-07-17	Agenus Inc.	anticorpos anti-ox40 e métodos de uso dos mesmos
WO2016183183A1 (en)	2015-05-11	2016-11-17	The Johns Hopkins University	Autoimmune antibodies for use in inhibiting cancer cell growth
EP3294768B1 (en)	2015-05-13	2019-08-21	Ablynx N.V.	T cell recruiting polypeptides based on tcr alpha/beta reactivity
DK3294319T3 (da)	2015-05-13	2024-07-22	Ablynx Nv	T-celle-rekrutterende polypeptider baseret på cd3-reaktivitet
KR101997241B1 (ko)	2015-05-21	2019-07-09	하푼 테라퓨틱스, 인크.	삼중특이성 결합 단백질 및 사용 방법
EP3302553A4 (en)	2015-05-28	2019-03-06	Bio-rad Laboratories, Inc.	AFFINITY LIGANDS AND APPROPRIATE PROCEDURES
PE20180672A1 (es)	2015-05-29	2018-04-19	Agenus Inc	Anticuerpos anti-ctla-4 y metodos de uso de los mismos
EA201792561A1 (ru)	2015-06-05	2018-04-30	Новартис Аг	Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
WO2016197367A1 (en)	2015-06-11	2016-12-15	Wuxi Biologics (Shanghai) Co. Ltd.	Novel anti-pd-l1 antibodies
WO2016207313A1 (en)	2015-06-24	2016-12-29	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and kits for detecting protein-protein interactions
JOP20200312A1 (ar)	2015-06-26	2017-06-16	Novartis Ag	الأجسام المضادة للعامل xi وطرق الاستخدام
AU2016294858B2 (en)	2015-07-17	2022-08-11	Vrije Universiteit Brussel	Radiolabelled antibody fragments for use in treating cancer
WO2017015427A1 (en)	2015-07-21	2017-01-26	Novartis Ag	Methods for improving the efficacy and expansion of immune cells
WO2017019894A1 (en)	2015-07-29	2017-02-02	Novartis Ag	Combination therapies comprising antibody molecules to lag-3
US20180207273A1 (en)	2015-07-29	2018-07-26	Novartis Ag	Combination therapies comprising antibody molecules to tim-3
EP3328418A1 (en)	2015-07-29	2018-06-06	Novartis AG	Combination therapies comprising antibody molecules to pd-1
GB2592821B (en)	2015-07-31	2022-01-12	Univ Minnesota	Modified cells and methods of therapy
WO2017023760A1 (en)	2015-07-31	2017-02-09	Prudent James R	Extracellular drug conjugates targeting cd20
CA2994516A1 (en)	2015-08-03	2017-02-09	Novartis Ag	Methods of treating fgf21-associated disorders
WO2017020291A1 (en)	2015-08-06	2017-02-09	Wuxi Biologics (Shanghai) Co. Ltd.	Novel anti-pd-l1 antibodies
AU2016306907A1 (en)	2015-08-07	2018-03-29	Merck Patent Gmbh	A transglutamine tag for efficient site-specific bioconjugation
CN105384825B (zh)	2015-08-11	2018-06-01	南京传奇生物科技有限公司	一种基于单域抗体的双特异性嵌合抗原受体及其应用
ES2992478T3 (es)	2015-08-11	2024-12-12	Wuxi Biologics Ireland Ltd	Nuevos anticuerpos anti-PD-1
ES2911015T3 (es)	2015-08-31	2022-05-17	Helixmith Co Ltd	Receptores quiméricos de antígeno anti-sialil Tn
CN107949573B (zh)	2015-09-01	2022-05-03	艾吉纳斯公司	抗-pd-1抗体及其使用方法
JP6905163B2 (ja)	2015-09-03	2021-07-21	ザトラスティーズオブザユニバーシティオブペンシルバニア	サイトカイン放出症候群を予測するバイオマーカー
MA55472A (fr)	2015-09-09	2022-02-09	Novartis Ag	Molécules de liaison de lymphopoïétine stromale thymique (tslp) et procédés d'utilisation des molécules
AU2016320748B2 (en)	2015-09-09	2019-05-02	Novartis Ag	Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
WO2017053469A2 (en)	2015-09-21	2017-03-30	Aptevo Research And Development Llc	Cd3 binding polypeptides
EP3359566A1 (en)	2015-10-07	2018-08-15	Alexion Pharmaceuticals, Inc.	A method for treating age-related macular degeneration in a patient
CN108699555A (zh)	2015-10-09	2018-10-23	萨勒普塔医疗公司	用于治疗杜兴肌营养不良和相关病症的组合物和方法
CN105238759B (zh) *	2015-10-14	2019-05-24	吉日木图	抗驼乳重链IgG3单克隆抗体、含有所述单克隆抗体的试纸及其应用
KR20180101341A (ko)	2015-11-10	2018-09-12	비스테라, 인크.	리포폴리사카라이드에 특이적으로 결합하는 항체 분자-약물 접합체 및 그의 용도
NO2768984T3 (da)	2015-11-12	2018-06-09
WO2017081190A1 (en)	2015-11-13	2017-05-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anti- nkg2d single domain antibodies and uses thereof
MA43259A (fr)	2015-11-18	2018-09-26	Merck Sharp & Dohme	Liants ctla4
IL300122A (en)	2015-11-18	2023-03-01	Merck Sharp ַ& Dohme Llc	Substances that bind to PD1 and/or LAG3
US20170145086A1 (en)	2015-11-25	2017-05-25	Visterra, Inc.	Antibody molecules to april and uses thereof
CA3006398A1 (en)	2015-11-27	2017-06-01	Ablynx Nv	Polypeptides inhibiting cd40l
CA3003200A1 (en)	2015-11-27	2017-06-01	Csl Limited	Cd131 binding proteins and uses thereof
MX380414B (es)	2015-12-04	2025-03-12	Boehringer Ingelheim Int	Polipeptidos biparatopicos que antagonizan la señalizacion wnt en celulas tumorales.
WO2017099712A1 (en)	2015-12-07	2017-06-15	Bluebird Bio, Inc.	Improved t cell compositions
EP3386542B1 (en)	2015-12-10	2020-11-18	Katholieke Universiteit Leuven	Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device
WO2017106129A1 (en)	2015-12-16	2017-06-22	Merck Sharp & Dohme Corp.	Anti-lag3 antibodies and antigen-binding fragments
CA3007421A1 (en)	2015-12-17	2017-06-22	Novartis Ag	Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
EP3389712B1 (en)	2015-12-17	2024-04-10	Novartis AG	Antibody molecules to pd-1 and uses thereof
WO2017103895A1 (en)	2015-12-18	2017-06-22	Novartis Ag	Antibodies targeting cd32b and methods of use thereof
CA3005696A1 (en)	2015-12-18	2017-06-22	Intervet International B.V.	Caninized human antibodies to human and canine il-4r alpha
US11091556B2 (en)	2015-12-18	2021-08-17	Intervet Inc.	Caninized human antibodies to human IL-4R alpha
EP3393504B1 (en)	2015-12-22	2025-09-24	Novartis AG	Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
WO2017117112A1 (en)	2015-12-28	2017-07-06	Novartis Ag	Methods of making chimeric antigen receptor -expressing cells
ES2981745T3 (es)	2016-02-05	2024-10-10	Orionis Biosciences BV	Agentes de señalización biespecíficos y usos de los mismos
AU2017219254B2 (en)	2016-02-17	2019-12-12	Novartis Ag	TGFbeta 2 antibodies
SG11201807489PA (en)	2016-03-04	2018-09-27	Novartis Ag	Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
EP3426278B1 (en)	2016-03-07	2024-01-03	Vib Vzw	Cd20 binding single domain antibodies
WO2017157305A1 (en)	2016-03-15	2017-09-21	Generon (Shanghai) Corporation Ltd.	Multispecific fab fusion proteins and use thereof
WO2017158396A1 (en)	2016-03-16	2017-09-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Cytidine deaminase inhibitors for the treatment of pancreatic cancer
WO2017162604A1 (en)	2016-03-21	2017-09-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosis and treatment of solar lentigo
AU2017238172B2 (en)	2016-03-21	2024-06-27	Marengo Therapeutics, Inc.	Multispecific and multifunctional molecules and uses thereof
JP7080213B2 (ja)	2016-03-23	2022-06-03	スーチョウトランセンタセラピューティクスカンパニー，リミテッド	新規抗ｐｄ－ｌ１抗体
TW201735949A (zh)	2016-03-24	2017-10-16	千禧製藥公司	治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
WO2017165778A1 (en)	2016-03-24	2017-09-28	Millennium Pharmaceuticals, Inc.	Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
TW202302144A (zh)	2016-03-25	2023-01-16	美商威特拉公司	登革病毒的抗體分子之配方設計
WO2017176762A1 (en)	2016-04-06	2017-10-12	Nanotics, Llc	Particles comprising subparticles or nucleic acid scaffolds
ES2866880T3 (es)	2016-04-13	2021-10-20	Inst Nat Sante Rech Med	Métodos y kits para la detección rápida del clon O25B-ST131 de Escherichia Coli
US11976116B2 (en)	2016-04-14	2024-05-07	2Seventy Bio, Inc.	Salvage chimeric antigen receptor systems
US20170298119A1 (en)	2016-04-15	2017-10-19	Visterra, Inc.	Antibody molecules to zika virus and uses thereof
SG11201809041TA (en)	2016-04-15	2018-11-29	Novartis Ag	Compositions and methods for selective protein expression
US11230591B2 (en)	2016-04-20	2022-01-25	Merck Sharp & Dohme Corp.	CMV neutralizing antigen binding proteins
WO2017182603A1 (en)	2016-04-22	2017-10-26	Université Libre de Bruxelles	A new biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
WO2017182605A1 (en)	2016-04-22	2017-10-26	Université Libre de Bruxelles	A new biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
WO2017189724A1 (en)	2016-04-27	2017-11-02	Novartis Ag	Antibodies against growth differentiation factor 15 and uses thereof
CN109415432B (zh)	2016-05-02	2022-07-08	普罗塞纳生物科学有限公司	Tau免疫疗法
US20190127447A1 (en)	2016-05-02	2019-05-02	Ablynx N.V.	Treatment of rsv infection
US11753463B2 (en)	2016-05-13	2023-09-12	Orionis Biosciences BV	Therapeutic targeting of non-cellular structures
MA55697A (fr)	2016-05-18	2022-02-23	Boehringer Ingelheim Int	Molécules d'anticorps pour le traitement du cancer
CN119060177A (zh)	2016-05-20	2024-12-03	哈普恩治疗公司	单结构域血清白蛋白结合蛋白质
BR112018073761A2 (pt)	2016-05-20	2019-02-26	Harpoon Therapeutics, Inc.	proteínas de ligação ao cd3 de fragmento variável de cadeia única
US11623958B2 (en)	2016-05-20	2023-04-11	Harpoon Therapeutics, Inc.	Single chain variable fragment CD3 binding proteins
EP3463452A1 (en)	2016-05-24	2019-04-10	Institut National de la Sante et de la Recherche Medicale (INSERM)	Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
TWI781934B (zh)	2016-05-27	2022-11-01	美商艾吉納斯公司	抗-tim-3抗體及其使用方法
US20170342139A1 (en)	2016-05-27	2017-11-30	Alexion Pharmaceuticals, Inc.	Methods for Treatment of Refractory Generalized Myasthenia Gravis
EP3463482B1 (en)	2016-06-07	2021-10-06	The Brigham and Women's Hospital, Inc.	Methods relating to t peripheral helper cells in autoantibody-associated conditions
AU2017283787B2 (en)	2016-06-15	2020-09-17	Novartis Ag	Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
WO2017223419A1 (en)	2016-06-24	2017-12-28	Ig Biosciences Corporation	Prebiotic neutraceutical compositions and methods of treatment using the same
WO2018007442A1 (en)	2016-07-06	2018-01-11	Ablynx N.V.	Treatment of il-6r related diseases
JP2019525772A (ja)	2016-07-08	2019-09-12	スターテン・バイオテクノロジー・ベー・フェー	抗ａｐｏｃ３抗体およびその使用方法
EP3484512A1 (en)	2016-07-13	2019-05-22	Biogen MA Inc.	Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders
US20190336504A1 (en)	2016-07-15	2019-11-07	Novartis Ag	Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
WO2018014260A1 (en)	2016-07-20	2018-01-25	Nanjing Legend Biotech Co., Ltd.	Multispecific antigen binding proteins and methods of use thereof
EP3487521A4 (en)	2016-07-21	2020-07-01	Emory University	ANTIBODIES AGAINST EBOLA VIRUS AND LIAISON AGENTS DERIVED THEREFROM
KR20250061769A (ko)	2016-07-28	2025-05-08	노파르티스 아게	키메라 항원 수용체 및 pd-1 억제제의 조합 요법
NL2017267B1 (en)	2016-07-29	2018-02-01	Aduro Biotech Holdings Europe B V	Anti-pd-1 antibodies
JP2019527696A (ja)	2016-08-01	2019-10-03	ノバルティスアーゲー	プロｍ２マクロファージ分子の阻害剤と組み合わせてキメラ抗原受容体を用いる癌の処置
NL2017270B1 (en)	2016-08-02	2018-02-09	Aduro Biotech Holdings Europe B V	New anti-hCTLA-4 antibodies
CA3032820A1 (en)	2016-08-02	2018-03-22	Visterra, Inc.	Engineered polypeptides and uses thereof
CA3032826A1 (en)	2016-08-03	2018-02-08	Nextcure, Inc.	Compositions and methods for modulating lair signal transduction
WO2018029182A1 (en)	2016-08-08	2018-02-15	Ablynx N.V.	Il-6r single variable domain antibodies for treatment of il-6r related diseases
WO2018050833A1 (en)	2016-09-15	2018-03-22	Ablynx Nv	Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
JP2020502991A (ja)	2016-09-20	2020-01-30	ウーシーバイオロジクスアイルランドリミテッド	新規抗ｐｃｓｋ９抗体
EP4360714A3 (en)	2016-09-21	2024-07-24	Nextcure, Inc.	Antibodies for siglec-15 and methods of use thereof
CN110035769A (zh)	2016-09-21	2019-07-19	奈斯科尔公司	针对siglec-15的抗体及其使用方法
AU2017331277B2 (en)	2016-09-23	2024-05-30	Marengo Therapeutics, Inc.	Multispecific antibody molecules comprising lambda and kappa light chains
CA3034105A1 (en)	2016-09-23	2018-03-29	Csl Limited	Coagulation factor binding proteins and uses thereof
WO2018060453A1 (en)	2016-09-30	2018-04-05	Vhsquared Limited	Compositions
JP7467117B2 (ja)	2016-10-07	2024-04-15	ノバルティスアーゲー	癌の治療のためのキメラ抗原受容体
AU2017343621B2 (en)	2016-10-11	2021-12-02	Agenus Inc.	Anti-LAG-3 antibodies and methods of use thereof
WO2018068201A1 (en)	2016-10-11	2018-04-19	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies and variants thereof against ctla-4
WO2018071624A1 (en)	2016-10-12	2018-04-19	Alexion Pharmaceuticals, Inc.	Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
GB2573406B (en)	2016-10-18	2021-11-10	Univ Minnesota	Tumor infiltrating lymphocytes and methods of therapy
JP7173965B2 (ja)	2016-10-19	2022-11-16	アレクシオンファーマシューティカルズ，インコーポレイテッド	試料中の非結合Ｃ５ａの定量化方法
JP7096240B2 (ja)	2016-10-19	2022-07-05	アレクシオンファーマシューティカルズ，インコーポレイテッド	試料中の非結合ｃ５の定量化方法
CN110291102A (zh)	2016-10-21	2019-09-27	国立卫生和医学研究所	促进t细胞应答的方法
US20200057046A1 (en)	2016-10-27	2020-02-20	Alexion Pharmaceuticals, Inc.	Assay for c5b-9 deposition in complement-associated disorders
JP7100030B2 (ja)	2016-10-28	2022-07-12	アスチュートメディカル，インコーポレイテッド	腎機能の改善のためのｔｉｍｐ－２に対する抗体の使用
WO2018078083A1 (en)	2016-10-28	2018-05-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	New method for treating multiple myeloma
WO2018083248A1 (en)	2016-11-03	2018-05-11	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses & methods
KR20190082241A (ko)	2016-11-04	2019-07-09	블루버드 바이오, 인코포레이티드.	항-bcma car t 세포 조성물
US11332521B2 (en)	2016-11-07	2022-05-17	Neuracle Science Co., Ltd.	Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
CA3043515A1 (en)	2016-11-16	2018-05-24	Ablynx Nv	T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
WO2018094244A1 (en)	2016-11-17	2018-05-24	Bluebird Bio, Inc.	TGFβ SIGNAL CONVERTOR
WO2018091720A1 (en)	2016-11-21	2018-05-24	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the prophylactic treatment of metastases
JP7215997B2 (ja)	2016-11-23	2023-01-31	ハープーンセラピューティクス，インク．	前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法
CA3044659A1 (en)	2016-11-23	2018-05-31	Harpoon Therapeutics, Inc.	Prostate specific membrane antigen binding protein
WO2018099968A1 (en)	2016-11-29	2018-06-07	Ablynx N.V.	Treatment of infection by respiratory syncytial virus (rsv)
WO2018102746A1 (en)	2016-12-02	2018-06-07	Rigel Pharmaceuticals, Inc.	Antigen binding molecules to tigit
CN118634323A (zh)	2016-12-07	2024-09-13	艾吉纳斯公司	抗体和其使用方法
JP2020508436A (ja)	2016-12-07	2020-03-19	プロジェニティ，インコーポレイテッド	胃腸管の検出方法、装置およびシステム
AU2017373944B2 (en)	2016-12-07	2022-02-03	Agenus Inc.	Anti-CTLA-4 antibodies and methods of use thereof
WO2018112240A1 (en)	2016-12-14	2018-06-21	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
US11597762B2 (en)	2016-12-14	2023-03-07	Biora Therapeutics, Inc.	Treatment of a disease of the gastrointestinal tract with an IL-12/IL-23 inhibitor released using an ingestible device
WO2018112264A1 (en)	2016-12-14	2018-06-21	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
BR112019012071A2 (pt)	2016-12-14	2019-11-12	Progenity Inc	tratamento de uma doença do trato gastrointestinal com um inibidor de integrina
EP3554346B1 (en)	2016-12-14	2024-01-31	Biora Therapeutics, Inc.	Treatment of a disease of the gastrointestinal tract with an immunosuppressant
US11134889B2 (en)	2016-12-14	2021-10-05	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with a SMAD7 inhibitor
EP4190318A1 (en)	2016-12-14	2023-06-07	Biora Therapeutics, Inc.	Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
WO2018112256A1 (en)	2016-12-14	2018-06-21	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
WO2018112237A1 (en)	2016-12-14	2018-06-21	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
EP3554344A1 (en)	2016-12-14	2019-10-23	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with a tlr modulator
EP3360898A1 (en)	2017-02-14	2018-08-15	Boehringer Ingelheim International GmbH	Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
CN110325550B (zh)	2016-12-23	2024-03-08	诺华股份有限公司	因子xi抗体和使用方法
IL267565B2 (en)	2016-12-23	2025-02-01	Visterra Inc	Methods of producing binding polypeptides containing covalently linked heavy chains and light chains
EP3565560B1 (en)	2017-01-09	2024-05-29	OnkosXcel Therapeutics, LLC	Predictive and diagnostic methods for prostate cancer
JP7303110B2 (ja)	2017-01-18	2023-07-04	ビステラ，インコーポレイテッド	抗体分子－薬物コンジュゲートおよびその使用
SG11201906540WA (en)	2017-01-19	2019-08-27	Open Monoclonal Tech Inc	Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
US11535662B2 (en)	2017-01-26	2022-12-27	Novartis Ag	CD28 compositions and methods for chimeric antigen receptor therapy
WO2018141753A1 (en)	2017-01-31	2018-08-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method for treating squamous cell carcinomas
US11384154B2 (en)	2017-02-06	2022-07-12	Orionis Biosciences BV	Targeted chimeric proteins and uses thereof
WO2018146594A1 (en)	2017-02-08	2018-08-16	Novartis Ag	Fgf21 mimetic antibodies and uses thereof
US20200291089A1 (en)	2017-02-16	2020-09-17	Elstar Therapeutics, Inc.	Multifunctional molecules comprising a trimeric ligand and uses thereof
CN110573604A (zh)	2017-02-28	2019-12-13	非营利性组织佛兰芒综合大学生物技术研究所	用于口服蛋白质递送的工具和方法
WO2018160754A2 (en)	2017-02-28	2018-09-07	Harpoon Therapeutics, Inc.	Inducible monovalent antigen binding protein
US20200048359A1 (en)	2017-02-28	2020-02-13	Novartis Ag	Shp inhibitor compositions and uses for chimeric antigen receptor therapy
EP3596464B1 (en)	2017-03-14	2021-08-11	NanoTag Biotechnologies GmbH	Target detection using a monovalent antibody
WO2018166495A1 (en)	2017-03-15	2018-09-20	Tsinghua University	Novel anti-trkb antibodies
WO2018167283A1 (en)	2017-03-17	2018-09-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
IL269083B2 (en)	2017-03-24	2024-12-01	Novartis Ag	Methods for preventing and treating heart disease
US20200330590A1 (en)	2017-03-27	2020-10-22	Celgene Corporation	Methods and compositions for reduction of immunogenicity
WO2018183932A1 (en)	2017-03-30	2018-10-04	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
EP3600249A1 (en)	2017-03-30	2020-02-05	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
CA3054947A1 (en)	2017-03-30	2018-10-04	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with live biotherapeutics
CA3054632A1 (en)	2017-03-30	2018-10-04	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
EP3600414A1 (en)	2017-03-30	2020-02-05	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
EP3606960A1 (en)	2017-04-03	2020-02-12	Oncologie, Inc.	Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
WO2018185516A1 (en)	2017-04-05	2018-10-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
WO2018189335A1 (en)	2017-04-13	2018-10-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
KR20240017409A (ko)	2017-04-13	2024-02-07	아게누스 인코포레이티드	항-cd137 항체 및 이의 사용 방법
WO2018189403A1 (en)	2017-04-14	2018-10-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of cancer
US20200033347A1 (en)	2017-04-18	2020-01-30	Universite Libre De Bruxelles	Biomarkers And Targets For Proliferative Diseases
US20200123238A1 (en)	2017-04-19	2020-04-23	Alexion Pharmaceuticals, Inc.	Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
WO2018195283A1 (en)	2017-04-19	2018-10-25	Elstar Therapeutics, Inc.	Multispecific molecules and uses thereof
AU2018255938A1 (en)	2017-04-21	2019-10-31	Staten Biotechnology B.V.	Anti-ApoC3 antibodies and methods of use thereof
EP3615068A1 (en)	2017-04-28	2020-03-04	Novartis AG	Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en)	2017-04-28	2020-03-04	Novartis AG	Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP4328241A3 (en)	2017-04-28	2024-06-05	Marengo Therapeutics, Inc.	Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
US11021537B2 (en)	2017-05-01	2021-06-01	Agenus Inc.	Anti-TIGIT antibodies and methods of use thereof
US11891451B2 (en)	2017-05-11	2024-02-06	Vib Vzw	Glycosylation of variable immunoglobulin domains
AU2018266562A1 (en)	2017-05-12	2019-12-05	Augusta University Research Institute, Inc.	Human alpha fetoprotein-specific T cell receptors and uses thereof
KR20200026810A (ko)	2017-05-12	2020-03-11	하푼 테라퓨틱스, 인크.	Msln 표적화 삼중 특이적 단백질 및 사용 방법
EP3621994A4 (en)	2017-05-12	2020-12-30	Harpoon Therapeutics, Inc.	MESOTHELIN BINDING PROTEINS
JOP20190256A1 (ar)	2017-05-12	2019-10-28	Icahn School Med Mount Sinai	فيروسات داء نيوكاسل واستخداماتها
WO2018222587A1 (en)	2017-05-30	2018-12-06	The Regents Of The University Of California	NANOBODIES AGAINST CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) INHIBITORY FACTOR (Cif)
US20210246227A1 (en)	2017-05-31	2021-08-12	Elstar Therapeutics, Inc.	Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
MX2019014331A (es)	2017-05-31	2020-01-27	Boehringer Ingelheim Int	Polipeptidos que antagonizan la se?alizacion wnt en celulas tumorales.
EP3630818A1 (en)	2017-06-02	2020-04-08	Ablynx NV	Aggrecan binding immunoglobulins
TWI826376B (zh)	2017-06-02	2023-12-21	德商麥克專利有限公司	與ａｄａｍｔｓ５、ｍｍｐ１３及聚集蛋白聚醣結合的多肽
KR20250036278A (ko)	2017-06-02	2025-03-13	메르크 파텐트 게엠베하	Mmp13 결합성 면역글로불린
MX2019014199A (es)	2017-06-02	2020-01-23	Boehringer Ingelheim Int	Tratamiento de combinacion antineoplasico.
KR20250011229A (ko)	2017-06-02	2025-01-21	메르크 파텐트 게엠베하	Adamts 결합성 면역글로불린
EP3415010A1 (en)	2017-06-13	2018-12-19	Agrosavfe Nv	Insect-controlling polypeptides and methods
GB201709379D0 (en)	2017-06-13	2017-07-26	Univ Leuven Kath	Humanised ADAMTS13 binding antibodies
WO2018229715A1 (en)	2017-06-16	2018-12-20	Novartis Ag	Compositions comprising anti-cd32b antibodies and methods of use thereof
US20190062428A1 (en)	2017-06-19	2019-02-28	Surface Oncology, Inc.	Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
CN110785187B (zh)	2017-06-22	2024-04-05	诺华股份有限公司	针对cd73的抗体分子及其用途
WO2018237173A1 (en)	2017-06-22	2018-12-27	Novartis Ag	Antibody molecules to cd73 and uses thereof
MX2019015738A (es)	2017-06-27	2020-02-20	Novartis Ag	Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
WO2019000223A1 (en)	2017-06-27	2019-01-03	Nanjing Legend Biotech Co., Ltd.	ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
EP3645041A4 (en)	2017-06-28	2021-03-17	The Rockefeller University	AGONISTIC ANTIBODY-ANTIBODY-ACTIVE INGREDIENT CONJUGATES AGAINST MERTK AND THEIR USES
RU2019143078A (ru)	2017-06-28	2021-07-28	Новартис Аг	Способы предупреждения и лечения недержания мочи
CN111511375A (zh)	2017-06-30	2020-08-07	因提玛生物科学公司	用于基因治疗的腺相关病毒载体
IL271920B2 (en)	2017-07-11	2024-03-01	Alexion Pharma Inc	Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
SG10201913144TA (en)	2017-07-11	2020-03-30	Compass Therapeutics Llc	Agonist antibodies that bind human cd137 and uses thereof
WO2019012030A1 (en)	2017-07-13	2019-01-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
EP3431496A1 (en)	2017-07-19	2019-01-23	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Anti- isoasp7 amyloid beta antibodies and uses thereof
WO2019016237A1 (en)	2017-07-19	2019-01-24	Vib Vzw	AGENTS FOR CONNECTING TO SERUM ALBUMIN
CN111163798A (zh)	2017-07-20	2020-05-15	诺华股份有限公司	用于抗lag-3抗体的给药方案及其用途
WO2019016784A1 (en)	2017-07-21	2019-01-24	Universidade De Coimbra	ANTI-NUCLEOLIN ANTIBODIES
US11174322B2 (en)	2017-07-24	2021-11-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antibodies and peptides to treat HCMV related diseases
US11365241B2 (en)	2017-07-27	2022-06-21	Alexion Pharmaceuticals, Inc.	High concentration anti-C5 antibody formulations
JP2020529605A (ja)	2017-08-01	2020-10-08	コンパスセラピューティクスリミテッドライアビリティカンパニー	濾過およびクロマトグラフィ用ポッドならびにその使用方法
WO2019036363A1 (en)	2017-08-14	2019-02-21	Progenity Inc.	TREATMENT OF GASTROINTESTINAL TRACT DISEASE WITH GLATIRAMER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
WO2019035938A1 (en)	2017-08-16	2019-02-21	Elstar Therapeutics, Inc.	MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
EP3684811A2 (en)	2017-08-17	2020-07-29	Massachusetts Institute of Technology	Multiple specificity binders of cxc chemokines and uses thereof
KR20200045520A (ko)	2017-09-07	2020-05-04	오거스타 유니버시티 리서치 인스티튜트, 인크.	프로그래밍된 세포사 단백질 1에 대한 항체
EP4512469A3 (en)	2017-09-11	2025-05-21	Monash University	Binding proteins to the human thrombin receptor, par4
EP3684471A1 (en)	2017-09-20	2020-07-29	Institut National de la Sante et de la Recherche Medicale (INSERM)	Methods and pharmaceutical compositions for modulating autophagy
EP3692069A1 (en)	2017-10-02	2020-08-12	Visterra, Inc.	Antibody molecules to cd138 and uses thereof
ES2759622T3 (es)	2017-10-02	2020-05-11	Certest Biotec S L	Anticuerpos anti-Dps y dispositivos de prueba para la detección de bacterias del género Campylobacter
WO2019075090A1 (en)	2017-10-10	2019-04-18	Tilos Therapeutics, Inc.	ANTI-LAP ANTIBODIES AND USES THEREOF
US11713356B2 (en)	2017-10-13	2023-08-01	Ose Immunotherapeutics	Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer
IL315737A (en)	2017-10-13	2024-11-01	Harpoon Therapeutics Inc	B-cell maturation antigen-binding proteins
CA3078969A1 (en)	2017-10-13	2019-04-18	Harpoon Therapeutics, Inc.	Trispecific proteins and methods of use
KR102715492B1 (ko)	2017-10-18	2024-10-11	씨에스엘 리미티드	인간 혈청 알부민 변이체 및 이의 용도
AU2018353432A1 (en)	2017-10-19	2020-04-23	Debiopharm International S.A.	Combination product for the treatment of cancer
US20210040205A1 (en)	2017-10-25	2021-02-11	Novartis Ag	Antibodies targeting cd32b and methods of use thereof
CN111566124A (zh)	2017-10-25	2020-08-21	诺华股份有限公司	制备表达嵌合抗原受体的细胞的方法
AU2018354404B2 (en)	2017-10-26	2025-10-30	Alexion Pharmaceuticals, Inc.	Dosage and administration of anti-C5 antibodies for treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS)
JP7039694B2 (ja)	2017-10-31	2022-03-22	スターテン・バイオテクノロジー・ベー・フェー	抗ａｐｏｃ３抗体およびその使用方法
WO2019089753A2 (en)	2017-10-31	2019-05-09	Compass Therapeutics Llc	Cd137 antibodies and pd-1 antagonists and uses thereof
WO2019089798A1 (en)	2017-10-31	2019-05-09	Novartis Ag	Anti-car compositions and methods
JP7760115B2 (ja)	2017-10-31	2025-10-27	フエー・イー・ベー・フエー・ゼツト・ウエー	新規抗原結合性キメラタンパク質とその方法及び使用
US20190160102A1 (en)	2017-11-03	2019-05-30	Rubius Therapeutics, Inc.	Compositions and methods related to therapeutic cell systems for tumor growth inhibition
AU2018368731A1 (en)	2017-11-16	2020-05-14	Novartis Ag	Combination therapies
US11851497B2 (en)	2017-11-20	2023-12-26	Compass Therapeutics Llc	CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
DK3717011T5 (da)	2017-11-29	2024-08-26	Csl Ltd	Fremgangsmåde til behandling eller forebyggelse af iskæmi-reperfusionsskade
WO2019106126A1 (en)	2017-12-01	2019-06-06	INSERM (Institut National de la Santé et de la Recherche Médicale)	Mdm2 modulators for the diagnosis and treatment of liposarcoma
JP2021505207A (ja)	2017-12-05	2021-02-18	セリアドエス．アー．ＣｅｌｙａｄＳ．Ａ．	Ｎｋｇ２ｄベースの受容体を発現する免疫細胞のフラトリサイドの減少
US12173316B2 (en)	2017-12-05	2024-12-24	Celyad S.A	Compositions and methods for improving persistence of cells for adoptive transfer
JP7348899B2 (ja)	2017-12-08	2023-09-21	マレンゴ・セラピューティクス，インコーポレーテッド	多重特異性分子及びその使用
WO2019121872A1 (en)	2017-12-20	2019-06-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the diagnosis and treatment of liver cancer
CN109970856B (zh)	2017-12-27	2022-08-23	信达生物制药(苏州)有限公司	抗lag-3抗体及其用途
WO2019129054A1 (zh)	2017-12-27	2019-07-04	信达生物制药(苏州)有限公司	三链抗体、其制备方法及其用途
WO2019129136A1 (zh)	2017-12-27	2019-07-04	信达生物制药(苏州)有限公司	抗pd-l1抗体及其用途
CN109970857B (zh)	2017-12-27	2022-09-30	信达生物制药(苏州)有限公司	抗pd-l1抗体及其用途
WO2019129137A1 (zh)	2017-12-27	2019-07-04	信达生物制药(苏州)有限公司	抗lag-3抗体及其用途
WO2019129221A1 (en)	2017-12-28	2019-07-04	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies and variants thereof against tigit
CN108218990B (zh)	2017-12-29	2021-03-02	南京优迈生物科技有限公司	分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用
EP3737692A4 (en)	2018-01-09	2021-09-29	Elstar Therapeutics, Inc.	CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
WO2019140116A2 (en)	2018-01-10	2019-07-18	Rubius Therapeutics, Inc.	Amplifiable rnas for therapeutic cell systems
KR20250114571A (ko)	2018-01-15	2025-07-29	난징 레전드 바이오테크 씨오., 엘티디.	Pd-1에 대한 단일-도메인 항체 및 이의 변이체
US11965191B2 (en)	2018-01-18	2024-04-23	California Institute Of Technology	Programmable protein circuits in living cells
EP3740231A4 (en)	2018-01-18	2022-03-23	California Institute of Technology	PROGRAMMABLE PROTEIN CIRCUITS IN LIVING CELLS
JP2021512151A (ja)	2018-01-23	2021-05-13	ネクストキュアインコーポレイテッド	Ｂ７−ｈ４抗体およびその使用方法
JP2021510594A (ja)	2018-01-25	2021-04-30	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	臓器の虚血再灌流傷害を予防する方法における使用のためのｉｌ−３３のアンタゴニスト
WO2019148089A1 (en)	2018-01-26	2019-08-01	Orionis Biosciences Inc.	Xcr1 binding agents and uses thereof
AU2019215031B2 (en)	2018-01-31	2025-10-09	Novartis Ag	Combination therapy using a chimeric antigen receptor
CA3089988A1 (en)	2018-02-01	2019-08-08	Memorial Sloan Kettering Cancer Center	Antibodies to galectin-3 and methods of use thereof
US12037382B2 (en)	2018-02-05	2024-07-16	Stichting Vu	Inverse agonistic anti-US28 antibodies
JP2021513361A (ja)	2018-02-05	2021-05-27	オリオニスバイオサイエンシーズ，インコーポレイテッド	線維芽細胞結合物質およびその使用
EP3749696A1 (en)	2018-02-06	2020-12-16	Ablynx N.V.	Methods of treating initial episode of ttp with immunoglobulin single variable domains
WO2019157191A1 (en)	2018-02-07	2019-08-15	Georgia Tech Research Corporation	Methods for multiplexed cell isolation using dna gates
WO2019155041A1 (en)	2018-02-12	2019-08-15	Vib Vzw	Gβγ COMPLEX ANTIBODIES AND USES THEREOF
WO2019156566A1 (en)	2018-02-12	2019-08-15	Umc Utrecht Holding B.V.	Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
WO2019158512A1 (en)	2018-02-13	2019-08-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the prognosis and the treatment of glioblastoma
WO2019160866A2 (en)	2018-02-13	2019-08-22	Checkmate Pharmaceuticals, Inc.	Compositions and methods for tumor immunotherapy
US11858960B2 (en)	2018-03-01	2024-01-02	Vrije Universiteit Brussel	Human PD-L1-binding immunoglobulins
US20210002373A1 (en)	2018-03-01	2021-01-07	Nextcure, Inc.	KLRG1 Binding Compositions and Methods of Use Thereof
NL2020520B1 (en)	2018-03-02	2019-09-12	Labo Bio Medical Invest B V	Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
MX2020009507A (es)	2018-03-13	2020-10-22	Smivet B V	Anticuerpos de dominio individual que se unen a la neurotoxina del tetanos.
EP4043496A1 (en)	2018-03-14	2022-08-17	Surface Oncology, Inc.	Antibodies that bind cd39 and uses thereof
US12152073B2 (en)	2018-03-14	2024-11-26	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to calreticulin and uses thereof
US20210009711A1 (en)	2018-03-14	2021-01-14	Elstar Therapeutics, Inc.	Multifunctional molecules and uses thereof
WO2019179420A1 (en)	2018-03-20	2019-09-26	Wuxi Biologics (Shanghai) Co., Ltd.	Novel anti-tim-3 antibodies
US11661452B2 (en)	2018-03-20	2023-05-30	WuXi Biologics Ireland Limited	Anti-lag-3 antibody polypeptide
US11332524B2 (en)	2018-03-22	2022-05-17	Surface Oncology, Inc.	Anti-IL-27 antibodies and uses thereof
US12281160B2 (en)	2018-03-23	2025-04-22	Csl Limited	Method of treating asthma
AU2019237215B2 (en)	2018-03-23	2023-11-02	Université Libre de Bruxelles	Wnt signaling agonist molecules
WO2019184909A1 (zh)	2018-03-27	2019-10-03	信达生物制药(苏州)有限公司	新型抗体分子、其制备方法及其用途
JP2021519093A (ja)	2018-03-27	2021-08-10	ユーエムシーユトレヒトホールディングビー．ブイ．	微小血管血栓症の処置のための標的化血栓溶解
US20210047696A1 (en)	2018-03-28	2021-02-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treating cancer
TW202003567A (zh)	2018-03-30	2020-01-16	大陸商南京傳奇生物科技有限公司	針對lag-3之單一結構域抗體及其用途
WO2019193375A1 (en)	2018-04-04	2019-10-10	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of fzd7 inhibitors for the treatment of retinal neovascularization
JP7511478B2 (ja)	2018-04-09	2024-07-05	チェックメイトファーマシューティカルズ	ウイルス様粒子中へのオリゴヌクレオチドのパッケージ化
WO2019200357A1 (en)	2018-04-12	2019-10-17	Surface Oncology, Inc.	Biomarker for cd47 targeting therapeutics and uses therefor
WO2019197683A1 (en)	2018-04-13	2019-10-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting outcome and treatment of patients suffering from prostate cancer or breast cancer
US20210147547A1 (en)	2018-04-13	2021-05-20	Novartis Ag	Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
WO2019207030A1 (en)	2018-04-26	2019-10-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
US20210047405A1 (en)	2018-04-27	2021-02-18	Novartis Ag	Car t cell therapies with enhanced efficacy
US12048745B2 (en)	2018-05-01	2024-07-30	Augusta University Research Institute, Inc.	Methods for detecting and reversing immune therapy resistance
WO2019211370A1 (en)	2018-05-03	2019-11-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treating cancer
WO2019211369A1 (en)	2018-05-03	2019-11-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for treating cancer
WO2019217913A1 (en)	2018-05-10	2019-11-14	Sensei Biotherapeutics, Inc.	Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof
EP3790898A4 (en)	2018-05-10	2022-03-02	Neuracle Science Co., Ltd	SEQUENCE-LIKE ANTI-FAMILY ANTIBODIES 19, MEMBER A5, AND METHOD OF USE THEREOF
CN119192397A (zh)	2018-05-14	2024-12-27	哈普恩治疗公司	用于条件性激活免疫球蛋白分子的结合部分
EP3569618A1 (en)	2018-05-19	2019-11-20	Boehringer Ingelheim International GmbH	Antagonizing cd73 antibody
WO2019226658A1 (en)	2018-05-21	2019-11-28	Compass Therapeutics Llc	Multispecific antigen-binding compositions and methods of use
EP3797120A1 (en)	2018-05-21	2021-03-31	Compass Therapeutics LLC	Compositions and methods for enhancing the killing of target cells by nk cells
WO2019226050A2 (en)	2018-05-24	2019-11-28	Wageningen Universiteit	Novel viral anti-infective reagents
UY38247A (es)	2018-05-30	2019-12-31	Novartis Ag	Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
JP7520725B2 (ja)	2018-05-31	2024-07-23	アレクシオンファーマシューティカルズ，インコーポレイテッド	小児患者における発作性夜間ヘモグロビン尿症（ｐｎｈ）の治療のための抗ｃ５抗体の用量および投与
US20210214459A1 (en)	2018-05-31	2021-07-15	Novartis Ag	Antibody molecules to cd73 and uses thereof
SG11202010579XA (en)	2018-06-01	2020-12-30	Novartis Ag	Binding molecules against bcma and uses thereof
US12460012B2 (en)	2018-06-04	2025-11-04	Alexion Pharmaceuticals, Inc.	Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) in pediatric patients
WO2019234099A1 (en)	2018-06-06	2019-12-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
WO2019234221A1 (en)	2018-06-08	2019-12-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
TWI848953B (zh)	2018-06-09	2024-07-21	德商百靈佳殷格翰國際股份有限公司	針對癌症治療之多特異性結合蛋白
WO2019241315A1 (en)	2018-06-12	2019-12-19	Obsidian Therapeutics, Inc.	Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2019241426A1 (en)	2018-06-13	2019-12-19	Novartis Ag	Bcma chimeric antigen receptors and uses thereof
CA3110836A1 (en)	2018-06-14	2019-12-19	Bluebird Bio, Inc.	Cd79a chimeric antigen receptors
CN113166266B (zh)	2018-06-18	2025-06-24	上海偌妥生物科技有限公司	抗间皮素构建体及其用途
CA3104295A1 (en)	2018-06-19	2019-12-26	Atarga, Llc	Antibody molecules to complement component 5 and uses thereof
US20230041197A1 (en)	2018-06-20	2023-02-09	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en)	2018-06-20	2025-02-18	Biora Therapeutics, Inc.	Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
EP3814373A1 (en)	2018-06-28	2021-05-05	Alexion Pharmaceuticals, Inc.	Methods of producing anti-c5 antibodies
CN118754985A (zh)	2018-06-29	2024-10-11	爱必泰生物有限公司	抗l1cam抗体及其用途
CN112351998B (zh)	2018-06-29	2022-07-22	苏州智核生物医药科技有限公司	Pd-l1结合多肽及其用途
JP7554742B2 (ja)	2018-07-03	2024-09-20	マレンゴ・セラピューティクス，インコーポレーテッド	抗ｔｃｒ抗体分子およびその使用
WO2020014333A1 (en)	2018-07-11	2020-01-16	Celgene Corporation	Uses of anti-bcma chimeric antigen receptors
WO2020014543A2 (en)	2018-07-11	2020-01-16	Actym Therapeutics, Inc.	Engineered immunostimulatory bacterial strains and uses thereof
WO2020016160A1 (en)	2018-07-16	2020-01-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method to treat neurological diseases
EP3823672A1 (en)	2018-07-19	2021-05-26	Institut National de la Santé et de la Recherche Médicale (INSERM)	Combination for treating cancer
CN112740043A (zh)	2018-07-20	2021-04-30	皮埃尔法布雷医药公司	Vista受体
WO2020021465A1 (en)	2018-07-25	2020-01-30	Advanced Accelerator Applications (Italy) S.R.L.	Method of treatment of neuroendocrine tumors
ES2738926A1 (es)	2018-07-26	2020-01-27	Univ Zaragoza	Granulisina, metodo de obtencion y usos
WO2020028909A1 (en)	2018-08-03	2020-02-06	Brown University	Oral formulations with increased uptake
US12460004B2 (en)	2018-08-09	2025-11-04	Compass Therapeutics Llc	Antibodies that bind CD277 and uses thereof
WO2020033925A2 (en)	2018-08-09	2020-02-13	Compass Therapeutics Llc	Antibodies that bind cd277 and uses thereof
WO2020033923A1 (en)	2018-08-09	2020-02-13	Compass Therapeutics Llc	Antigen binding agents that bind cd277 and uses thereof
US12391957B2 (en)	2018-08-17	2025-08-19	Icahn School Of Medicine At Mount Sinai	Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease
US11453893B2 (en)	2018-08-30	2022-09-27	California Institute Of Technology	RNA-based delivery systems with levels of control
US20210171909A1 (en)	2018-08-31	2021-06-10	Novartis Ag	Methods of making chimeric antigen receptor?expressing cells
WO2020047320A1 (en)	2018-08-31	2020-03-05	California Institute Of Technology	Synthetic protein circuits detecting signal transducer activity
AU2019331496A1 (en)	2018-08-31	2021-03-18	Novartis Ag	Methods of making chimeric antigen receptor-expressing cells
CN112585169A (zh)	2018-09-04	2021-03-30	南京优迈生物科技有限公司	融合蛋白及其在制备用于治疗肿瘤和/或病毒感染的药物中的应用
GB201814451D0 (en)	2018-09-05	2018-10-17	Valerie Nicholas Carl Kristoffer	Methods
GB2576914A (en)	2018-09-06	2020-03-11	Kymab Ltd	Antigen-binding molecules comprising unpaired variable domains produced in mammals
WO2020048525A1 (en)	2018-09-07	2020-03-12	Generon (Shanghai) Corporation Ltd.	Bispecific antigen binding proteins and uses thereof
US12365705B2 (en)	2018-09-11	2025-07-22	Nanotag Biotechnologies Gmbh	Epitope tags recognized by specific binders
US12195544B2 (en)	2018-09-21	2025-01-14	Harpoon Therapeutics, Inc.	EGFR binding proteins and methods of use
US12473357B2 (en)	2018-09-25	2025-11-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of antagonists of Th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
US10815311B2 (en)	2018-09-25	2020-10-27	Harpoon Therapeutics, Inc.	DLL3 binding proteins and methods of use
JP7465272B2 (ja)	2018-09-27	2024-04-10	マレンゴ・セラピューティクス，インコーポレーテッド	Ｃｓｆ１ｒ／ｃｃｒ２多特異性抗体
BR112021004383A2 (pt)	2018-09-28	2021-08-03	Massachusetts Institute Of Technology	proteína de fusão imunomoduladora, composição farmacêutica, ácido nucleico, vetor de expressão, célula transformada, método para a produção de uma proteína de fusão imunomoduladora, método para ativar, aumentar ou promover uma resposta por uma célula imune em um sujeito, método para inibir, reduzir ou suprimir uma resposta por uma célula imune em um sujeito, método para reduzir ou inibir o crescimento do tumor, método para tratar câncer em um sujeito, kit, uso de uma proteína de fusão imunomoduladora e método para reduzir ou inibir o crescimento do tumor ou tratar o câncer em um sujeito
WO2020070062A1 (en)	2018-10-01	2020-04-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of tim-3 inhibitors for the treatment of exacerbations in patients suffering from severe asthma
JP2022504287A (ja)	2018-10-03	2022-01-13	スターテン・バイオテクノロジー・ベー・フェー	ヒト及びカニクイザルａｐｏｃ３に特異的な抗体、並びにその使用の方法
WO2020070288A1 (en)	2018-10-05	2020-04-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and systems for controlling the agonistic properties of antibody variable domains by light
US11130802B2 (en)	2018-10-10	2021-09-28	Tilos Therapeutics, Inc.	Anti-lap antibody variants
UY38407A (es)	2018-10-15	2020-05-29	Novartis Ag	Anticuerpos estabilizadores de trem2
WO2020080941A1 (en)	2018-10-16	2020-04-23	Umc Utrecht Holding B.V.	Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
US20210386788A1 (en)	2018-10-24	2021-12-16	Obsidian Therapeutics, Inc.	Er tunable protein regulation
WO2020092549A1 (en)	2018-10-30	2020-05-07	Alexion Pharmaceuticals, Inc.	Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
US20220000893A1 (en)	2018-10-31	2022-01-06	\|Nserm (Institut National De La Santé Et De La Recherche Médicale)	Method for treating t-helper type 2 mediated disease
WO2020097350A1 (en)	2018-11-08	2020-05-14	Orionis Biosciences, Inc.	Modulation of dendritic cell lineages
GB201818477D0 (en)	2018-11-13	2018-12-26	Emstopa Ltd	Tissue plasminogen activator antibodies and method of use thereof
AU2019379576A1 (en)	2018-11-13	2021-06-03	Compass Therapeutics Llc	Multispecific binding constructs against checkpoint molecules and uses thereof
US12422441B2 (en)	2018-12-07	2025-09-23	Georgia Tech Research Corporation	Antibodies that bind to natively folded myocilin
WO2020120644A1 (en)	2018-12-13	2020-06-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	New anti tau svqivykpv epitope single domain antibody
CA3121420A1 (en)	2018-12-13	2020-06-18	Surface Oncology, Inc.	Anti-il-27 antibodies and uses thereof
WO2020128894A1 (en)	2018-12-20	2020-06-25	Novartis Ag	Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer
US20230071889A1 (en)	2018-12-21	2023-03-09	Ose Immunotherapeutics	Bifunctional anti-pd-1/il-7 molecule
AU2019409805A1 (en)	2018-12-21	2021-07-22	Ose Immunotherapeutics	Bifunctional anti-PD-1/SIRPA molecule
WO2020127369A1 (en)	2018-12-21	2020-06-25	Ose Immunotherapeutics	Bifunctional molecule directed against human pd-1
WO2020130838A2 (en)	2018-12-21	2020-06-25	Qvq Holding B.V.	Antibodies for preventing or treating candidiasis
KR20220008253A (ko)	2019-01-03	2022-01-20	엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름)	암을 앓는 대상에서 cd8+ t 세포 의존성 면역 반응을 향상시키기 위한 방법 및 약학적 조성물
BR112021013337A2 (pt)	2019-01-07	2021-11-09	Bactolife Aps	Proteínas de ligação a patógenos
EP3908653A4 (en)	2019-01-10	2022-11-02	California Institute of Technology	A synthetic system for tunable thresholding of protein signals
JP7645185B2 (ja)	2019-01-15	2025-03-13	アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル	変異したインターロイキン－３４（ｉｌ－３４）ポリペプチドおよび治療におけるその使用
JP2022522265A (ja)	2019-01-16	2022-04-15	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	エリスロフェロンの変異体及びその使用
KR20210131312A (ko)	2019-01-16	2021-11-02	콤파스 테라퓨틱스 엘엘씨	인간 cd137에 결합하는 항체의 제제 및 이의 용도
TWI756621B (zh)	2019-01-25	2022-03-01	大陸商信達生物製藥（蘇州）有限公司	新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體
GB201901608D0 (en)	2019-02-06	2019-03-27	Vib Vzw	Vaccine adjuvant conjugates
WO2020165374A1 (en)	2019-02-14	2020-08-20	Ose Immunotherapeutics	Bifunctional molecule comprising il-15ra
US10871640B2 (en)	2019-02-15	2020-12-22	Perkinelmer Cellular Technologies Germany Gmbh	Methods and systems for automated imaging of three-dimensional objects
CA3129834A1 (en)	2019-02-15	2020-08-20	Integral Molecular, Inc.	Claudin 6 antibodies and uses thereof
JP2022520632A (ja)	2019-02-15	2022-03-31	インテグラル・モレキュラー・インコーポレイテッド	共通軽鎖を含む抗体及びその使用
WO2020169707A1 (en)	2019-02-21	2020-08-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Foxo1 inhibitor for use in the treatment of latent virus infection
CN114127112A (zh)	2019-02-21	2022-03-01	马伦戈治疗公司	与t细胞结合的多功能分子及其治疗自身免疫性病症的用途
EP3927744A1 (en)	2019-02-21	2021-12-29	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to t cell related cancer cells and uses thereof
CN114127111B (zh)	2019-02-21	2024-09-10	马伦戈治疗公司	与nkp30结合的抗体分子及其用途
SG11202109056TA (en)	2019-02-21	2021-09-29	Marengo Therapeutics Inc	Multifunctional molecules that bind to calreticulin and uses thereof
AU2020226904B2 (en)	2019-02-21	2025-05-01	Marengo Therapeutics, Inc.	Anti-TCR antibody molecules and uses thereof
WO2020172553A1 (en)	2019-02-22	2020-08-27	Novartis Ag	Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
ES2978570T3 (es)	2019-02-26	2024-09-16	Inspirna Inc	Anticuerpos anti-MERTK de alta afinidad y sus usos
EP3930757A1 (en)	2019-03-01	2022-01-05	President And Fellows Of Harvard College	Methods and compositions for protein delivery
WO2020185069A1 (en)	2019-03-08	2020-09-17	Linxis B.V.	Internalizing binding molecules targeting receptors involved in cell proliferation or cell differentiation
SG11202109172TA (en)	2019-03-08	2021-09-29	Obsidian Therapeutics Inc	Human carbonic anhydrase 2 compositions and methods for tunable regulation
WO2020198731A2 (en)	2019-03-28	2020-10-01	Danisco Us Inc	Engineered antibodies
WO2020193740A1 (en)	2019-03-28	2020-10-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	New strategy for treating pancreatic cancer
KR20220029546A (ko)	2019-03-29	2022-03-08	아타르가, 엘엘씨	항 fgf23 항체
US12291562B2 (en)	2019-04-01	2025-05-06	Rush University Medical Center	Reagents and assays using modified integrin domains
JP2022527825A (ja)	2019-04-03	2022-06-06	プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ	薬物送達のためのイオン液体
US12331133B2 (en)	2019-04-04	2025-06-17	Vanderbilt University	Therapeutic antibodies for treating lung cancer
WO2020208082A1 (en)	2019-04-09	2020-10-15	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method for treating cmv related diseases
EP3953455A1 (en)	2019-04-12	2022-02-16	Novartis AG	Methods of making chimeric antigen receptor-expressing cells
CN114041056A (zh)	2019-04-29	2022-02-11	康福治疗有限公司	用于跨膜蛋白尤其是gpcr的筛选方法和测定
US20220289837A1 (en)	2019-04-30	2022-09-15	Vib Vzw	Cystic Fibrosis Transmembrane Conductance Regulator Stabilizing Agents
KR20220007586A (ko)	2019-05-13	2022-01-18	리제너론 파마슈티칼스 인코포레이티드	개선된 경쟁적 리간드 결합 검정
EP3969479B1 (en)	2019-05-14	2025-07-30	Harpoon Therapeutics, Inc.	Epcam binding proteins and methods of use
JP2022533591A (ja)	2019-05-14	2022-07-25	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	リンホトキシンアルファ遮断剤によりターゲットされた制御性ｔ細胞及びその使用
EP3969472A1 (en)	2019-05-16	2022-03-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method to treat type 2 inflammation or mast-cell dependent disease
WO2020236797A1 (en)	2019-05-21	2020-11-26	Novartis Ag	Variant cd58 domains and uses thereof
EP3972998A1 (en)	2019-05-21	2022-03-30	Novartis AG	Cd19 binding molecules and uses thereof
CN118994397A (zh)	2019-05-21	2024-11-22	诺华股份有限公司	针对bcma的三特异性结合分子及其用途
EP3978532A4 (en)	2019-05-24	2023-10-18	Sanyou Biopharmaceuticals Co., Ltd.	Novel cldn18.2 binding molecule
EP3976650A1 (en)	2019-05-28	2022-04-06	Vib Vzw	Cancer treatment by targeting plexins in the immune compartment
WO2020239934A1 (en)	2019-05-28	2020-12-03	Vib Vzw	Cd8+ t-cells lacking plexins and their application in cancer treatment
GB2584441A (en)	2019-06-03	2020-12-09	Fenomark Diagnostics Ab	Medical uses, methods and uses
CN113474372B (zh)	2019-06-04	2023-08-08	上海吉倍生物技术有限公司	一种抗ceacam5的单克隆抗体及其制备方法和用途
PH12021553101A1 (en)	2019-06-12	2023-10-02	Novartis Ag	Natriuretic peptide receptor 1 antibodies and methods of use
EP3983442A2 (en)	2019-06-17	2022-04-20	Visterra, Inc.	Humanized antibody molecules to cd138 and uses thereof
WO2020254619A1 (en)	2019-06-20	2020-12-24	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anti- protease nexin-1 conformational single domain antibodies and uses thereof
US20220242945A1 (en)	2019-06-21	2022-08-04	Sorriso Pharmaceuticals, Inc.	Polypeptides
AU2020295767A1 (en)	2019-06-21	2022-02-17	Sorriso Pharmaceuticals, Inc.	Compositions
WO2020254827A1 (en)	2019-06-21	2020-12-24	Vhsquared Limited	Polypeptides
EP3990491A1 (en)	2019-06-26	2022-05-04	Massachusetts Institute of Technology	Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
WO2021000886A1 (zh)	2019-07-01	2021-01-07	苏州康宁杰瑞生物科技有限公司	百日咳毒素结合蛋白
WO2021001539A1 (en)	2019-07-04	2021-01-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	New strategy to detect and treat eosinophilic fasciitis
BR112022000721A2 (pt)	2019-07-15	2022-03-08	Intervet Int Bv	Anticorpos caninizados contra ctla-4 canina
TWI889694B (zh)	2019-07-26	2025-07-11	美商威特拉公司	介白素-2藥劑及其用途
US20220324947A1 (en)	2019-08-05	2022-10-13	Stichting Vu	Identification and Elimination of HCMV-Infected Cells
CR20220076A (es)	2019-08-30	2022-06-24	Agenus Inc	Anticuerpos anti-cd96 y sus métodos de uso
TWI873176B (zh)	2019-09-04	2025-02-21	美商建南德克公司	Ｃｄ８結合劑及其用途
WO2021044012A1 (en)	2019-09-05	2021-03-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method of treatment and pronostic of acute myeloid leukemia
US20220348937A1 (en)	2019-09-06	2022-11-03	Obsidian Therapeutics, Inc.	Compositions and methods for dhfr tunable protein regulation
EP4031178A1 (en)	2019-09-16	2022-07-27	Surface Oncology, Inc.	Anti-cd39 antibody compositions and methods
TW202124446A (zh)	2019-09-18	2021-07-01	瑞士商諾華公司	與ｅｎｔｐｄ２抗體之組合療法
US20220348651A1 (en)	2019-09-18	2022-11-03	Novartis Ag	Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
US20210115127A1 (en)	2019-09-25	2021-04-22	Surface Oncology, Inc.	Anti-il-27 antibodies and uses thereof
US20220290151A1 (en)	2019-09-27	2022-09-15	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of müllerian inhibiting substance inhibitors for treating cancer
TW202126295A (zh)	2019-09-27	2021-07-16	大陸商江蘇挪貝肽醫藥科技有限公司	一種治療心境障礙的方法
TWI878355B (zh)	2019-10-02	2025-04-01	德商百靈佳殷格翰國際股份有限公司	用於癌症治療之多重專一性結合蛋白
EP3799881A1 (en)	2019-10-04	2021-04-07	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Single domain antibodies specifically binding globo - series glycans
EP4048703A1 (en)	2019-10-21	2022-08-31	Vib Vzw	Nanodisc-specific antigen-binding chimeric proteins
KR20220103947A (ko)	2019-10-21	2022-07-25	노파르티스 아게	베네토클락스 및 tim-3 억제제를 사용한 조합 요법
CA3157665A1 (en)	2019-10-21	2021-04-29	Novartis Ag	Tim-3 inhibitors and uses thereof
WO2021080682A1 (en)	2019-10-24	2021-04-29	Massachusetts Institute Of Technology	Monoclonal antibodies that bind human cd161 and uses thereof
US20230002785A1 (en)	2019-10-28	2023-01-05	Georgia Tech Research Corporation	Mrna-encoded antibodies for contraception
US20240148901A1 (en)	2019-10-28	2024-05-09	Georgia Tech Research Corporation	Compositions and methods for prophylaxis of hiv
CN115697387A (zh)	2019-11-05	2023-02-03	细胞基因公司	抗bcma嵌合抗原受体的用途
JP2023501004A (ja)	2019-11-11	2023-01-17	アイビーアイ－エージーイノベイティブバイオインセクティサイズリミテッド	昆虫防除ナノボディおよびその使用
JP2023501539A (ja)	2019-11-12	2023-01-18	アクティム・セラピューティクス・インコーポレイテッド	免疫刺激細菌デリバリープラットフォーム、および治療用産物のデリバリーのためのその使用
CA3158963A1 (en)	2019-11-22	2021-05-27	Samir Mitragotri	Ionic liquids for drug delivery
MX2022006391A (es)	2019-11-26	2022-06-24	Novartis Ag	Receptores de antigeno quimerico que se unen a bcma y cd19 y usos de los mismos.
WO2021105438A1 (en)	2019-11-27	2021-06-03	Vib Vzw	Positive allosteric modulators of the calcium-sensing receptor
WO2021105391A1 (en)	2019-11-27	2021-06-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Combination comprising nupr1 inhibitors to treat cancer
WO2021105384A1 (en)	2019-11-27	2021-06-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Targeting the nls region of nupr1 protein to treat cancer
CN115151309A (zh)	2019-12-05	2022-10-04	Ose免疫疗法	抗clec-1a抗体及其抗原结合片段
MX2022006881A (es)	2019-12-06	2022-07-11	Ablynx Nv	Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa y ox40l.
JP7657797B2 (ja)	2019-12-06	2025-04-07	アブリンクスエン．ヴェー．	ＴＮＦαおよびＩＬ－２３を標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
US11897950B2 (en)	2019-12-06	2024-02-13	Augusta University Research Institute, Inc.	Osteopontin monoclonal antibodies
US20230040928A1 (en)	2019-12-09	2023-02-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antibodies having specificity to her4 and uses thereof
EP4072674A1 (en)	2019-12-09	2022-10-19	Ablynx N.V.	Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp
GB201918279D0 (en)	2019-12-12	2020-01-29	Vib Vzw	Glycosylated single chain immunoglobulin domains
AU2020406083A1 (en)	2019-12-17	2022-06-16	Boehringer Ingelheim International Gmbh	Bifunctional molecules comprising an IL-7 variant
WO2021123996A1 (en)	2019-12-20	2021-06-24	Novartis Ag	Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
EP4076525A4 (en)	2019-12-20	2024-05-01	Momenta Pharmaceuticals, Inc.	ANTIBODIES AGAINST INTEGRIN ALPHA 11 BETA 1
AU2020404453B2 (en)	2019-12-20	2022-12-08	Hudson Institute of Medical Research	CXCL10 binding proteins and uses thereof
EP4077372A1 (en)	2019-12-20	2022-10-26	Vib Vzw	Nanobody exchange chromatography
WO2021138407A2 (en)	2020-01-03	2021-07-08	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to cd33 and uses thereof
IL321341A (en)	2020-01-06	2025-08-01	Vaccinex Inc	Anti-CCR8 antibodies and their uses
WO2021140205A1 (en)	2020-01-10	2021-07-15	Confo Therapeutics N.V.	Methods for generating antibodies and antibody fragments and libraries comprising same
TWI869528B (zh)	2020-01-13	2025-01-11	美商威特拉公司	C5ar1抗體分子及其用途
AU2021207348A1 (en)	2020-01-17	2022-08-11	Novartis Ag	Combination comprising a TIM-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
CA3162913A1 (en)	2020-01-17	2021-07-22	Universiteit Gent	Immunoglobulin single domain antibodies for delivery of mucosal vaccines
WO2021156490A2 (en)	2020-02-06	2021-08-12	Vib Vzw	Corona virus binders
US20230111593A1 (en)	2020-02-14	2023-04-13	Novartis Ag	Method of predicting response to chimeric antigen receptor therapy
CN115768463A (zh)	2020-02-21	2023-03-07	哈普恩治疗公司	Flt3结合蛋白及使用方法
JP2023515131A (ja)	2020-02-24	2023-04-12	イマティクスユーエス，アイエヌシー．	がんおよび関連する悪性腫瘍の治療のためにｔ細胞を増殖させる方法
US20230087785A1 (en)	2020-02-25	2023-03-23	Vib Vzw	Leucine-Rich Repeat Kinase 2 Allosteric Modulators
WO2021173674A1 (en)	2020-02-26	2021-09-02	A2 Biotherapeutics, Inc.	Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
EP4110377A2 (en)	2020-02-27	2023-01-04	Novartis AG	Methods of making chimeric antigen receptor-expressing cells
CN115175695A (zh)	2020-02-27	2022-10-11	诺华股份有限公司	制备表达嵌合抗原受体的细胞的方法
WO2021183675A2 (en)	2020-03-10	2021-09-16	Massachusetts Institute Of Technology	Methods for generating engineered memory-like nk cells and compositions thereof
CN115485295A (zh)	2020-03-10	2022-12-16	麻省理工学院	NPM1c阳性癌症的免疫疗法的组合物和方法
DE102020111571A1 (de)	2020-03-11	2021-09-16	Immatics US, Inc.	Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
BR112022018088A2 (pt)	2020-03-12	2023-01-17	Immune Onc Therapeutics Inc	Novos anticorpos anti-lilrb4 e produtos derivados
WO2021180205A1 (zh)	2020-03-13	2021-09-16	江苏恒瑞医药股份有限公司	Pvrig结合蛋白及其医药用途
EP4121756A1 (en)	2020-03-20	2023-01-25	GlaxoSmithKline Intellectual Property Development Limited	Method for detecting polysorbates
US11365239B2 (en)	2020-03-20	2022-06-21	Tsb Therapeutics (Beijing) Co., Ltd.	Anti-SARS-COV-2 antibodies and uses thereof
CN116249549A (zh)	2020-03-27	2023-06-09	诺华股份有限公司	用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
MX2022012278A (es)	2020-03-30	2022-10-27	Ablynx Nv	Metodo para la produccion y purificacion de dominios variables unicos de inmunoglobulina multivalentes.
CN113461817B (zh)	2020-03-31	2025-04-18	苏州泽璟生物制药股份有限公司	一种抗人cd47抗体及其抗原结合片段、制备方法和应用
AU2021250446A1 (en)	2020-03-31	2022-11-17	Biotalys NV	Anti-fungal polypeptides
AU2021248643A1 (en)	2020-04-03	2022-10-27	Visterra, Inc.	Antibody molecule-drug conjugates and uses thereof
US20230272056A1 (en)	2020-04-09	2023-08-31	Merck Sharp & Dohme Llc	Affinity matured anti-lap antibodies and uses thereof
AU2021257848A1 (en)	2020-04-15	2022-12-01	Voyager Therapeutics, Inc.	Tau binding compounds
JP2023522208A (ja)	2020-04-16	2023-05-29	アシスタンスピュブリック－オピトドパリ	ウイルスによって引き起こされる補体媒介性障害を処置する方法
CN113527488A (zh)	2020-04-22	2021-10-22	迈威(上海)生物科技股份有限公司	一种靶向人程序性死亡配体1（pd-l1）的单可变域抗体及其衍生物
CA3180321A1 (en)	2020-04-24	2021-10-28	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to t cell related cancer cells and uses thereof
US20230176070A1 (en)	2020-05-01	2023-06-08	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	Compositions and methods for identifying nanobodies and nanobody affinities
IL297412A (en)	2020-05-04	2022-12-01	Immunorizon Ltd	Precursor tri-specific antibody constructs and methods of use thereof
CN115551553A (zh)	2020-05-12	2022-12-30	Inserm(法国国家健康医学研究院)	治疗皮肤t细胞淋巴瘤和tfh起源淋巴瘤的新方法
WO2021229104A1 (en)	2020-05-15	2021-11-18	Université de Liège	Anti-cd38 single-domain antibodies in disease monitoring and treatment
CA3180665A1 (en)	2020-05-19	2021-11-25	Boehringer Ingelheim International Gmbh	Binding molecules for the treatment of cancer
EP4424711A3 (en)	2020-05-19	2024-10-23	Institut Curie	Methods for the diagnosis and treatment of cytokine release syndrome
EP3916088A1 (en)	2020-05-28	2021-12-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Fusion proteins comprising the sars-cov-2 3clpro catalytic domain and their uses for screening anti-sars-cov-2 agents
WO2021242794A2 (en)	2020-05-29	2021-12-02	President And Fellows Of Harvard College	Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
CR20220611A (es)	2020-06-02	2023-06-07	Arcus Biosciences Inc	Anticuerpos anti-tigit
CN111647077B (zh)	2020-06-02	2021-02-09	深圳市因诺赛生物科技有限公司	新型冠状病毒(sars-cov-2)刺突蛋白结合分子及其应用
CA3185455A1 (en)	2020-06-11	2021-12-16	Novartis Ag	Zbtb32 inhibitors and uses thereof
TW202214844A (zh)	2020-06-17	2022-04-16	美商健生生物科技公司	用於製造多能幹細胞之材料及方法
US20230218608A1 (en)	2020-06-18	2023-07-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	New strategy for treating pancreatic cancer
AU2021297315A1 (en)	2020-06-24	2023-02-02	Visterra, Inc.	Antibody molecules to APRIL and uses thereof
AU2021299932A1 (en)	2020-06-29	2023-02-02	Assistance Publique-Hôpitaux De Paris (Aphp)	Anti-protein S single-domain antibodies and polypeptides comprising thereof
US12077576B2 (en)	2020-07-02	2024-09-03	Trustees Of Tufts College	VHH polypeptides that bind to Clostridium difficile toxin b and methods of use thereof
WO2022003156A1 (en)	2020-07-02	2022-01-06	Oncurious Nv	Ccr8 non-blocking binders
CN115803348A (zh)	2020-07-03	2023-03-14	苏州康宁杰瑞生物科技有限公司	凝血因子xi(fxi)结合蛋白
MX2023000547A (es)	2020-07-16	2023-02-13	Novartis Ag	Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas.
EP4186925A4 (en)	2020-07-21	2025-01-22	Suzhou Smartnuclide Biopharmaceutical Co., Ltd.	CD8-BINDING POLYPEPTIDE AND USE THEREOF
TW202216760A (zh)	2020-07-23	2022-05-01	愛爾蘭商歐薩爾普羅席納有限公司	抗類澱粉β (ABETA)抗體
WO2022026592A2 (en)	2020-07-28	2022-02-03	Celltas Bio, Inc.	Antibody molecules to coronavirus and uses thereof
IL300173A (en)	2020-07-31	2023-03-01	Biotalys NV	Expression host
WO2022036159A2 (en)	2020-08-12	2022-02-17	Actym Therapeutics, Inc.	Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
WO2022040631A1 (en)	2020-08-21	2022-02-24	Immatics US, Inc.	Methods for isolating cd8+ selected t cells
CN116917316A (zh)	2020-08-26	2023-10-20	马伦戈治疗公司	与NKp30结合的抗体分子及其用途
EP4204450A4 (en)	2020-08-26	2024-11-13	Marengo Therapeutics, Inc.	MULTIFUNCTIONAL CALRETICULIN-BINDING MOLECULES AND RELATED USES
EP4204458A4 (en)	2020-08-26	2024-10-09	Marengo Therapeutics, Inc.	METHODS FOR DETECTION OF TRBC1 OR TRBC2
WO2022043558A1 (en)	2020-08-31	2022-03-03	Advanced Accelerator Applications International Sa	Method of treating psma-expressing cancers
EP4204021A1 (en)	2020-08-31	2023-07-05	Advanced Accelerator Applications International S.A.	Method of treating psma-expressing cancers
KR20230069961A (ko)	2020-09-14	2023-05-19	보르 바이오파마 인크.	Cd33에 대한 단일 도메인 항체
EP4214235A1 (en)	2020-09-16	2023-07-26	LinXis B.V.	Internalizing binding molecules
WO2022060806A1 (en)	2020-09-16	2022-03-24	Obsidian Therapeutics, Inc.	Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
WO2022063947A1 (en)	2020-09-24	2022-03-31	Vib Vzw	Combination of p2y6 inhibitors and immune checkpoint inhibitors
WO2022063957A1 (en)	2020-09-24	2022-03-31	Vib Vzw	Biomarker for anti-tumor therapy
WO2022063984A1 (en)	2020-09-25	2022-03-31	Ablynx Nv	Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
WO2022081804A1 (en)	2020-10-14	2022-04-21	Viridian Therapeutics, Inc.	Compositions and methods for treatment of thyroid eye disease
WO2022084399A1 (en)	2020-10-21	2022-04-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	C-terminal sparc fragments for treating cancer
WO2022084355A2 (en)	2020-10-21	2022-04-28	Boehringer Ingelheim International Gmbh	Agonistic trkb binding molecules for the treatment of eye diseases
WO2022098685A2 (en)	2020-11-04	2022-05-12	Celgene Corporation	Car t cell therapy in patients who have had prior anti-cancer alkylator therapy
CA3199839A1 (en)	2020-11-06	2022-05-12	Novartis Ag	Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
US20240025993A1 (en)	2020-11-06	2024-01-25	Novartis Ag	Cd19 binding molecules and uses thereof
CN112480248B (zh)	2020-11-24	2023-05-05	三优生物医药(上海)有限公司	与cld18a2特异性结合的分子
EP4255929A2 (en)	2020-12-02	2023-10-11	Vib Vzw	An ltbr agonist in combination therapy against cancer
WO2022117569A1 (en)	2020-12-02	2022-06-09	Oncurious Nv	A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
US20240016936A1 (en)	2020-12-04	2024-01-18	Celgene Corporation	Uses of chimeric antigen receptor (car) t-cell therapies in combination with inhibitors of inflammation-related soluble factors
MX2023006599A (es)	2020-12-04	2023-06-19	Visterra Inc	Metodos de uso de agentes de interleucina-2.
PH12023500013A1 (en)	2020-12-04	2024-03-11	Tidal Therapeutics Inc	Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
US20240052042A1 (en)	2020-12-14	2024-02-15	Novartis Ag	Reversal binding agents for anti-natriuretic peptide receptor i (npri) antibodies and uses thereof
KR20230129441A (ko)	2020-12-17	2023-09-08	오제 이뮈노테라프틱스	이기능성 항-pd1/il-7 분자
KR20230123495A (ko)	2020-12-18	2023-08-23	아블린쓰 엔.브이.	글리피칸-3 및 t세포 수용체를 표적으로 하는 면역글로불린단일 가변 도메인을 포함하는 폴리펩티드
JP2023553694A (ja)	2020-12-18	2023-12-25	アブリンクスエン．ヴェー．	ＩＬ－６およびＴＮＦ－αを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
WO2022129637A1 (en)	2020-12-18	2022-06-23	Ablynx Nv	T cell recruiting polypeptides based on tcr alpha/beta reactivity
GB202020502D0 (en)	2020-12-23	2021-02-03	Vib Vzw	Antibody composistion for treatment of corona virus infection
EP4267617A1 (en)	2020-12-24	2023-11-01	Vib Vzw	Human ccr8 binders
WO2022136650A1 (en)	2020-12-24	2022-06-30	Oncurious Nv	Murine cross-reactive human ccr8 binders
EP4267618A1 (en)	2020-12-24	2023-11-01	Vib Vzw	Non-blocking human ccr8 binders
MX2023008598A (es)	2021-01-20	2023-08-10	Visterra Inc	Agentes de interleuquina-2 y usos de los mismos.
GB2603166A (en)	2021-01-29	2022-08-03	Thelper As	Therapeutic and Diagnostic Agents and Uses Thereof
EP4284510A1 (en)	2021-01-29	2023-12-06	Novartis AG	Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
AU2022214006A1 (en)	2021-02-01	2023-09-21	St Phi Therapeutics Co., Ltd.	Targeted protein degradation system and use thereof
AU2022217812A1 (en)	2021-02-05	2023-08-03	Salubris Biotherapeutics, Inc.	Il-15 fusion proteins and methods of making and using same
US20240101647A1 (en)	2021-02-05	2024-03-28	Vib Vzw	Sarbecovirus binders
CN117794566A (zh)	2021-02-05	2024-03-29	Vib研究所	沙贝病毒结合剂
EP4291898A1 (en)	2021-02-12	2023-12-20	Institut National de la Santé et de la Recherche Médicale (INSERM)	Method for prognosis and treating a patient suffering from cancer
CN117241804A (zh)	2021-02-17	2023-12-15	非营利性组织佛兰芒综合大学生物技术研究所	在癌症治疗中slc4a4的抑制
KR102836732B1 (ko)	2021-02-19	2025-07-21	(주)샤페론	Pd-l1에 대한 단일 도메인 항체 및 이의 용도
AU2022222994B2 (en)	2021-02-19	2025-11-27	Shaperon Inc.	Single domain antibody against cd47 and use thereof
MX2023009715A (es)	2021-02-19	2024-01-08	Shaperon Inc	Anticuerpo de dominio individual biespecífico contra el ligando de muerte programada (pd-l1) y el cúmulo de diferenciación 47 (cd47) y uso del mismo.
EP4294516A1 (en)	2021-02-19	2023-12-27	Vib Vzw	Cation-independent mannose-6-phosphate receptor binders
AU2022224636A1 (en)	2021-02-19	2023-09-07	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Single domain antibodies that neutralize sars-cov-2
CN117321418A (zh)	2021-03-18	2023-12-29	诺华股份有限公司	癌症生物标志物及其使用方法
GB202104104D0 (en)	2021-03-24	2021-05-05	Liliumx Ltd	Platform and method
WO2022199804A1 (en)	2021-03-24	2022-09-29	Vib Vzw	Nek6 inhibition to treat als and ftd
JP2024514530A (ja)	2021-04-02	2024-04-02	ザリージェンツオブザユニバーシティオブカリフォルニア	切断型ｃｄｃｐ１に対する抗体およびその使用
CN117441010A (zh)	2021-04-07	2024-01-23	世纪治疗股份有限公司	从诱导多能干细胞产生α-βT细胞的组合物和方法
IL307358A (en)	2021-04-07	2023-11-01	Century Therapeutics Inc	Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells
TW202304979A (zh)	2021-04-07	2023-02-01	瑞士商諾華公司	抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AU2022253223A1 (en)	2021-04-07	2023-09-28	Century Therapeutics, Inc.	Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
GB2623199A (en)	2021-04-08	2024-04-10	Marengo Therapeutics Inc	Multifunctional molecules binding to TCR and uses thereof
US20240369570A1 (en)	2021-04-09	2024-11-07	Stichting Radboud Universiteit	Off the shelf proximity biotinylation enzyme
EP4320156A1 (en)	2021-04-09	2024-02-14	Ose Immunotherapeutics	Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
WO2022214653A1 (en)	2021-04-09	2022-10-13	Ose Immunotherapeutics	New scaffold for bifunctional molecules with improved properties
WO2022219076A1 (en)	2021-04-14	2022-10-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	New method to improve the anti-tumoral activity of macrophages
WO2022219080A1 (en)	2021-04-14	2022-10-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	New method to improve nk cells cytotoxicity
IL307598A (en)	2021-04-16	2023-12-01	Juno Therapeutics Inc	T-cell therapy in patients who have had a previous stem cell transplant
AU2022270075A1 (en)	2021-05-04	2023-11-09	Regeneron Pharmaceuticals, Inc.	Multispecific fgf21 receptor agonists and their uses
CA3215856A1 (en)	2021-05-07	2022-11-10	Alison O'neill	Anti-il-27 antibodies and uses thereof
WO2022242892A1 (en)	2021-05-17	2022-11-24	Université de Liège	Anti-cd38 single-domain antibodies in disease monitoring and treatment
US12252550B2 (en)	2021-05-20	2025-03-18	Dianthus Therapeutics Opco, Inc.	Antibodies that bind to C1S and uses thereof
WO2022253910A1 (en)	2021-06-02	2022-12-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	A new method to treat an inflammatory skin disease
JP2024523436A (ja)	2021-06-16	2024-06-28	上海▲シン▼湾生物科技有限公司	Ａｘｌタンパク質を標的とする抗体及びその抗原結合断片、その調製方法と使用
EP4355778A1 (en)	2021-06-17	2024-04-24	Boehringer Ingelheim International GmbH	Novel tri-specific binding molecules
AU2022299282A1 (en)	2021-06-22	2024-02-01	Merck Patent Gmbh	Vhh-based nkp30 binders
US20230174651A1 (en)	2021-06-23	2023-06-08	Janssen Biotech, Inc.	Materials and methods for hinge regions in functional exogenous receptors
CN114230665B (zh)	2021-06-23	2024-03-22	苏州智核生物医药科技有限公司	CD8α结合多肽及其用途
US20240287501A1 (en)	2021-06-23	2024-08-29	Vib Vzw	Means and Methods for Selection of Specific Binders
JP2024524378A (ja)	2021-06-29	2024-07-05	山▲東▼先声生物制▲薬▼有限公司	Ｃｄ１６抗体及びその応用
WO2023288046A1 (en)	2021-07-15	2023-01-19	President And Fellows Of Harvard College	Compositions and methods relating to cells with adhered particles
WO2023006040A1 (zh)	2021-07-30	2023-02-02	江苏先声药业有限公司	抗pvrig/抗tigit双特异性抗体和应用
CA3228014A1 (en)	2021-07-30	2023-02-16	Vib Vzm	Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
EP4380691A1 (en)	2021-08-06	2024-06-12	Institut Régional du Cancer de Montpellier (ICM)	Methods for the treatment of cancer
EP4384219A4 (en)	2021-08-10	2025-06-18	Viridian Therapeutics, Inc.	COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE
WO2023023220A1 (en)	2021-08-20	2023-02-23	Alexion Pharmaceuticals, Inc.	Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor
WO2023023227A1 (en)	2021-08-20	2023-02-23	Alexion Pharmaceuticals, Inc.	Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors
MX2024002261A (es)	2021-08-24	2024-03-06	Jiangsu Hengrui Pharmaceuticals Co Ltd	Molecula de union de fap/cd40 y uso medicinal de la misma.
CN117940453A (zh)	2021-09-15	2024-04-26	江苏恒瑞医药股份有限公司	特异性结合pd-1的蛋白及其医药用途
WO2023041985A2 (en)	2021-09-15	2023-03-23	New York University In Abu Dhabicorporation	Compositions that block activation of the sars-cov-2 replication and transcription complex (rtc) and methods of use thereof
CA3231553A1 (en)	2021-09-15	2023-03-23	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody
WO2023041744A1 (en)	2021-09-17	2023-03-23	Institut Curie	Bet inhibitors for treating pab1 deficient cancer
EP4405680A1 (en)	2021-09-20	2024-07-31	Institut National de la Santé et de la Recherche Médicale (INSERM)	Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
US20250223376A1 (en)	2021-09-20	2025-07-10	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of her2 positive cancer
WO2023057484A1 (en)	2021-10-06	2023-04-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy
WO2023057601A1 (en)	2021-10-06	2023-04-13	Biotalys NV	Anti-fungal polypeptides
AU2022359915A1 (en)	2021-10-08	2024-05-02	President And Fellows Of Harvard College	Ionic liquids for drug delivery
KR20240082411A (ko)	2021-10-14	2024-06-10	라띠콘 (수저우) 바이오파마슈티칼스 코., 엘티디.	신규 항체-사이토카인 융합 단백질, 이의 제조 방법 및 이의 용도
WO2023073099A1 (en)	2021-10-28	2023-05-04	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method to improve phagocytosis
WO2023078906A1 (en)	2021-11-03	2023-05-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method for treating acute myeloid leukemia
EP4177266A1 (en)	2021-11-05	2023-05-10	Katholieke Universiteit Leuven	Neutralizing anti-sars-cov-2 human antibodies
WO2023079137A1 (en)	2021-11-05	2023-05-11	Katholieke Universiteit Leuven	Neutralizing anti-sars-cov-2 human antibodies
CN118510534A (zh)	2021-11-09	2024-08-16	Ose免疫疗法	Clec-1配体的识别及其用途
EP4429682A2 (en)	2021-11-09	2024-09-18	Actym Therapeutics, Inc.	Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment
EP4180518A1 (en)	2021-11-12	2023-05-17	Istituto Europeo di Oncologia S.r.l.	T cells and uses thereof
WO2023092004A1 (en)	2021-11-17	2023-05-25	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of tau-related disorders
EP4433089A1 (en)	2021-11-19	2024-09-25	Institut Curie	Methods for the treatment of hrd cancer and brca-associated cancer
CN118302818A (zh)	2021-11-22	2024-07-05	阿布林克斯有限公司	获得目标多价免疫球蛋白单可变结构域的序列信息
WO2023089159A1 (en)	2021-11-22	2023-05-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	New strategy targeting stroma/tumor cell crosstalk to treat a cancer
EP4436982A1 (en)	2021-11-24	2024-10-02	Novartis AG	Modulators of adeno-associated virus transduction and uses thereof
US20230348614A1 (en)	2021-11-24	2023-11-02	Visterra, Inc.	Engineered antibody molecules to cd138 and uses thereof
CN118339179A (zh)	2021-11-29	2024-07-12	江苏恒瑞医药股份有限公司	经修饰的蛋白或多肽
CN116199782A (zh)	2021-11-30	2023-06-02	苏州康宁杰瑞生物科技有限公司	预防和/或治疗血栓栓塞性疾病的方法
TW202333772A (zh)	2021-12-01	2023-09-01	美商威特拉公司	使用介白素-2藥劑之方法
WO2023099763A1 (en)	2021-12-03	2023-06-08	Institut Curie	Sirt6 inhibitors for use in treating resistant hrd cancer
JP2024541668A (ja)	2021-12-03	2024-11-08	山▲東▼先声生物制▲薬▼有限公司	抗ｂｃｍａナノ抗体及びその応用
WO2023114884A2 (en)	2021-12-15	2023-06-22	Interius Biotherapeutics, Inc.	Pseudotyped viral particles, compositions comprising the same, and uses thereof
WO2023111266A1 (en)	2021-12-17	2023-06-22	Ablynx Nv	POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123
CN118510805A (zh)	2021-12-31	2024-08-16	山东先声生物制药有限公司	一种gprc5d抗体及其应用
EP4209508A1 (en)	2022-01-11	2023-07-12	Centre national de la recherche scientifique	Nanobodies for the deneddylating enzyme nedp1
WO2023135198A1 (en)	2022-01-12	2023-07-20	Vib Vzw	Human ntcp binders for therapeutic use and liver-specific targeted delivery
GB202201137D0 (en)	2022-01-28	2022-03-16	Thelper As	Therapeutic and diagnostic agents and uses thereof
KR20240137086A (ko)	2022-01-28	2024-09-19	조지아뮨 인코포레이티드	Pd-1 작용제인 세포예정사 단백질 1에 대한 항체
US20250129387A1 (en)	2022-02-02	2025-04-24	Biotalys NV	Methods for genome editing
WO2023148397A1 (en)	2022-02-07	2023-08-10	Vib Vzw	Engineered stabilizing aglycosylated fc-regions
US20230383010A1 (en)	2022-02-07	2023-11-30	Visterra, Inc.	Anti-idiotype antibody molecules and uses thereof
JP2025507371A (ja)	2022-02-11	2025-03-18	ヘンケル・アクチェンゲゼルシャフト・ウント・コムパニー・コマンディットゲゼルシャフト・アウフ・アクチェン	α－メチレン－γ－ブチロラクトンを合成する方法
US20250144042A1 (en)	2022-02-22	2025-05-08	Brown University	Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
CA3246434A1 (en)	2022-03-23	2023-09-28	Bodhi Bio Llc	COMPOSITIONS AND METHODS FOR SPECIFIC ANTIGEN THERAPY
US20250223370A1 (en)	2022-03-30	2025-07-10	Novartis Ag	Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies
US20250333515A1 (en)	2022-04-11	2025-10-30	Vor Biopharma Inc.	Binding agents and methods of use thereof
EP4508082A1 (en)	2022-04-13	2025-02-19	Vib Vzw	An ltbr agonist in combination therapy against cancer
JP2025512483A (ja)	2022-04-13	2025-04-17	オーエスイー・イミュノセラピューティクス	抗体を選択的に排除するための分子の新規のクラス
WO2023198851A1 (en)	2022-04-14	2023-10-19	Institut National de la Santé et de la Recherche Médicale	Methods for controlling the tumor cell killing by light
US20240092921A1 (en)	2022-04-25	2024-03-21	Visterra, Inc.	Antibody molecules to april and uses thereof
EP4514390A1 (en)	2022-04-28	2025-03-05	The United States of America, as represented by the Secretary, Department of Health and Human Services	Recombinant polypeptides comprising single-domain antibodies targeting herv-k subtype hml-2
US20250289904A1 (en)	2022-05-02	2025-09-18	Umc Utrecht Holding B.V.	Single domain antibodies for the detection of plasmin-cleaved vwf
WO2023215719A1 (en)	2022-05-02	2023-11-09	Arcus Biosciences, Inc.	Anti-tigit antibodies and uses of the same
EP4524156A4 (en)	2022-05-07	2025-10-22	Beijing Tuo Jie Biopharmaceutical Co Ltd	RELAXIN FUSION PROTEIN OR ANALOGUE AND ITS MEDICAL USE
JP2025517657A (ja)	2022-05-10	2025-06-10	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	シンシチン－１融合タンパク質及び標的細胞へのカーゴ送達のためのその使用
JP2025516629A (ja)	2022-05-11	2025-05-30	セルジーンコーポレーション	Ｔ細胞療法に関連する方法および使用、ならびにその生成
WO2023220647A1 (en)	2022-05-11	2023-11-16	Regeneron Pharmaceuticals, Inc.	Multispecific binding molecule proproteins and uses thereof
WO2023220695A2 (en)	2022-05-13	2023-11-16	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of her2 positive cancer
TWI866210B (zh)	2022-05-17	2024-12-11	大陸商蘇州創勝醫藥集團有限公司	雙功能蛋白質及其製劑和用途
IL316708A (en)	2022-05-18	2024-12-01	Vib Vzw	Cerbevirus S2 spike subunit binding
US20230372395A1 (en)	2022-05-19	2023-11-23	Massachusetts Institute Of Technology	Car cells targeting an inserted ligand
WO2023224412A1 (ko)	2022-05-19	2023-11-23	(주)샤페론	Pd-l1 및 cd47에 대한 이중특이적 인간화 단일 도메인 항체 및 이의 용도
US20240025987A1 (en)	2022-05-25	2024-01-25	Surface Oncology, Inc.	Use of anti-il-27 antibodies
US20240026001A1 (en)	2022-05-25	2024-01-25	Surface Oncology, Inc.	Use of anti-il-27 antibodies
US20250345432A1 (en)	2022-05-25	2025-11-13	Celgene Corporation	Method for predicting response to a t cell therapy
CN119301276A (zh)	2022-05-30	2025-01-10	Ose免疫疗法	Il7r调节剂活性的生物标志物
JP2025518269A (ja)	2022-05-31	2025-06-12	明済生物製薬（北京）有限公司	抗ｃｄ４０抗体と抗ｐｄ－ｌ１×ｃｄ４０二重特異性抗体及びその使用
IL317463A (en)	2022-06-06	2025-02-01	Shandong Simcere Biopharmaceutical Co Ltd	Multispecific antibodies targeting BCMA, GPRC5D and T cells and their application
KR20250035053A (ko)	2022-06-07	2025-03-11	리제너론 파아마슈티컬스, 인크.	T 세포 활성을 조절하기 위한 다중특이적 분자 및 이의 용도
EP4536836A1 (en)	2022-06-07	2025-04-16	Regeneron Pharmaceuticals, Inc.	Pseudotyped viral particles for targeting tcr-expressing cells
US20240002331A1 (en)	2022-06-08	2024-01-04	Tidal Therapeutics, Inc.	Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
AU2023290487A1 (en)	2022-06-14	2025-01-30	Ablynx Nv	Immunoglobulin single variable domains targeting t cell receptor
EP4299124A1 (en)	2022-06-30	2024-01-03	Universite De Montpellier	Anti-mglur2 nanobodies for use as biomolecule transporter
EP4299125A1 (en)	2022-06-30	2024-01-03	Universite De Montpellier	Anti-mglur2 biparatopic nanobodies and uses thereof
WO2024003873A1 (en)	2022-06-30	2024-01-04	Intrexon Actobiotics Nv D/B/A Precigen Actobio	Single variable domain antibodies against tumor necrosis factor-alpha
US20250304677A1 (en)	2022-07-04	2025-10-02	Vib Vzw	Blood-Cerebrospinal Fluid Barrier Crossing Antibodies
CA3259753A1 (en)	2022-07-08	2024-01-11	Novo Nordisk As	HIGHLY POTENT ISVD COMPOUNDS CAPABLE OF REPLACED FVIII(A)
AR129879A1 (es)	2022-07-08	2024-10-09	Novo Nordisk As	Compuestos de isvd altamente potentes capaces de sustituir al fviii(a)
PE20250669A1 (es)	2022-07-15	2025-03-04	Boehringer Ingelheim Int	Moleculas de union para el tratamiento del cancer
KR20250040019A (ko)	2022-07-18	2025-03-21	아블린쓰	Cx3cr1 결합 화합물, 이의 용도, 및 관련 방법
US20250188492A1 (en)	2022-07-22	2025-06-12	Janssen Biotech, Inc.	Enhanced Transfer of Genetic Instructions to Effector Immune Cells
EP4562155A2 (en)	2022-07-25	2025-06-04	Interius Biotherapeutics, Inc.	Mutated polypeptides, compositions comprising the same, and uses thereof
JP2025526384A (ja)	2022-07-27	2025-08-13	アブリンクスエン．ヴェー．	新生児型Ｆｃ受容体の特異的エピトープに結合するポリペプチド
JP2025525884A (ja)	2022-08-01	2025-08-07	オーエスイー・イミュノセラピューティクス	ヘテロ二量体Ｆｃ－ＣＬＥＣ－１融合分子及びその使用
CN119907811A (zh)	2022-08-02	2025-04-29	Ose免疫疗法公司	针对cd28的多功能分子
TW202435912A (zh)	2022-08-03	2024-09-16	美商航海家醫療公司	用於穿過血腦屏障之組合物及方法
WO2024028476A1 (en)	2022-08-05	2024-02-08	Institut National de la Santé et de la Recherche Médicale	Methods for the treatment of th2-mediated diseases
WO2024037910A1 (en)	2022-08-17	2024-02-22	Institut National de la Santé et de la Recherche Médicale	Syk inhibitors for use in the treatment of cancer
EP4577578A1 (en)	2022-08-22	2025-07-02	Abdera Therapeutics Inc.	Dll3 binding molecules and uses thereof
EP4580749A1 (en)	2022-08-31	2025-07-09	Alexion Pharmaceuticals, Inc.	Dosage and administration of fusion polypeptides for treatment of sickle cell disease
JP2025528459A (ja)	2022-08-31	2025-08-28	アンスティテュナショナルドゥラサンテエドゥラルシェルシュメディカル（インセルム）	より効率的なｃａｒ－ｔ細胞を生成する方法
JP2025529210A (ja)	2022-09-01	2025-09-04	ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド	アポリポタンパク質ｌ１を導いて哺乳動物の細胞死を誘導するための組成物及び方法
CN120035450A (zh)	2022-09-06	2025-05-23	阿雷克森制药公司	造血干细胞移植物相关血栓性微血管病（hsct-tma）患者的诊断和预后生物标志物谱
WO2024228717A2 (en)	2022-09-07	2024-11-07	Quantitative Biosciences, Inc.	Fentanyl-specific single variable-domain antibodies and use in a continuous agglutination assay
AU2023338626A1 (en)	2022-09-09	2025-03-20	Yale University	Proteolysis targeting antibodies and methods of use thereof
IL319225A (en)	2022-09-15	2025-04-01	Novartis Ag	Treatment of autoimmune disorders using antigen receptor chemotherapeutics
AU2023342086A1 (en)	2022-09-15	2025-03-13	Voyager Therapeutics, Inc.	Tau binding compounds
EP4594348A1 (en)	2022-09-27	2025-08-06	Vib Vzw	Antivirals against human parainfluenza virus
KR20250131767A (ko)	2022-09-28	2025-09-03	발린크 테라퓨틱스 리미티드	다가 단백질 및 스크리닝 방법
TW202430561A (zh)	2022-09-30	2024-08-01	法商賽諾菲公司	抗cd28抗體
WO2024074713A1 (en)	2022-10-07	2024-04-11	Institut National de la Santé et de la Recherche Médicale	Method to generate improving car-t cells
WO2024083843A1 (en)	2022-10-18	2024-04-25	Confo Therapeutics N.V.	Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
CN120322456A (zh)	2022-10-28	2025-07-15	嘉和生物药业有限公司	新型抗ctla4抗体
WO2024096735A1 (en)	2022-10-31	2024-05-10	Stichting Amsterdam UMC	Single domain anti-cd169 antibodies
CN117986361A (zh)	2022-11-02	2024-05-07	苏州康宁杰瑞生物科技有限公司	一种gipr结合蛋白及其应用
EP4615493A1 (en)	2022-11-08	2025-09-17	Stichting Amsterdam UMC	Activation inducible antigen receptors for adoptive immunotherapy
CN120584135A (zh)	2022-11-10	2025-09-02	英姆维亚公司	结合dr5和muc16的细胞毒性双特异性抗体及其用途
JP2025537809A (ja)	2022-11-15	2025-11-20	アイメック・ヴェーゼットウェー	液滴操作のための方法およびシステム
US12110344B2 (en)	2022-11-21	2024-10-08	Dianthus Therapeutics Opco, Inc.	Antibodies that bind to cis and uses thereof
TW202421667A (zh)	2022-11-29	2024-06-01	大陸商江蘇恆瑞醫藥股份有限公司	Ｃｌｄｎ１８．２／４－１ｂｂ結合蛋白及其醫藥用途
TW202430574A (zh)	2022-11-30	2024-08-01	美商積分分子股份有限公司	針對密連蛋白６之抗體，包括其雙特異性格式
AU2023406483A1 (en)	2022-12-01	2025-05-29	Generation Bio Co.	Stealth lipid nanoparticle compositions for cell targeting
WO2024123963A2 (en)	2022-12-07	2024-06-13	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing monoclonal antibodies against western, eastern, and venezuelan equine encephalitis virus (eev)
WO2024126363A1 (en)	2022-12-12	2024-06-20	Institut National de la Santé et de la Recherche Médicale	Image-based high-content screening methods for identifying compounds targeting apicomplexan parasites
AU2023394987A1 (en)	2022-12-15	2025-06-26	Aarhus Universitet	Synthetic activation of multimeric transmembrane receptors
US12195546B2 (en)	2022-12-19	2025-01-14	Sanofi	CD28/OX40 bispecific antibodies
AU2023410327A1 (en)	2022-12-19	2025-06-05	Umc Utrecht Holding B.V.	Btn2a1 binding peptide
CN120380024A (zh)	2022-12-21	2025-07-25	建新公司	抗pd-1×4-1bb结合蛋白
WO2024133723A1 (en)	2022-12-22	2024-06-27	Institut National de la Santé et de la Recherche Médicale	Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy
EP4638735A1 (en)	2022-12-22	2025-10-29	Biotalys NV	Methods for genome editing
AR131494A1 (es)	2022-12-23	2025-03-26	Ablynx Nv	Vehículos de conjugación a base de proteína
EP4640715A1 (en)	2022-12-23	2025-10-29	Chimagen Biosciences, Ltd	Multi-specific polypeptide complex targeting gprc5d
WO2024145551A1 (en)	2022-12-29	2024-07-04	Biotalys NV	Agrochemical compositions
EP4643878A2 (en)	2022-12-29	2025-11-05	Suzhou Transcenta Therapeutics Co., Ltd.	Pharmaceutical preparation comprising therapeutic antibody and use thereof
EP4642232A1 (en)	2022-12-30	2025-11-05	Biotalys NV	Self-emulsifiable concentrate
EP4642916A2 (en)	2022-12-30	2025-11-05	Biotalys NV	Secretion signals
WO2024141645A1 (en)	2022-12-30	2024-07-04	Biotalys N.V.	Agglomerate
EP4647771A1 (en)	2022-12-30	2025-11-12	UIF (University Industry Foundation), Yonsei University	Antibody or peptide binding specifically to rnase a, immunoassay device and method for detecting rnase a, and method for collecting rnase a
TW202434643A (zh)	2023-01-09	2024-09-01	大陸商北京拓界生物醫藥科技有限公司	ＴＧＦβ１結合分子、ＧＡＲＰ－ＴＧＦβ１結合分子及其醫藥用途
KR20250133750A (ko)	2023-01-09	2025-09-08	오디세이 테라퓨틱스, 인코포레이티드	항-tnfr2 항원-결합 단백질 및 그의 용도
US20240247069A1 (en)	2023-01-13	2024-07-25	Regeneron Pharmaceuticals, Inc.	Fgfr3 binding molecules and methods of use thereof
TW202434629A (zh)	2023-01-26	2024-09-01	愛爾蘭商歐薩爾普羅席納有限公司	以抗類澱粉β (ABETA)抗體治療神經病症之方法
EP4655324A1 (en)	2023-01-27	2025-12-03	Vib Vzw	Cd163-binding conjugates
WO2024156881A1 (en)	2023-01-27	2024-08-02	Vib Vzw	CD8b-BINDING POLYPEPTIDES
KR20250143339A (ko)	2023-02-06	2025-10-01	메르크 파텐트 게엠베하	VHH-기반 NKp46 결합제
WO2024168061A2 (en)	2023-02-07	2024-08-15	Ayan Therapeutics Inc.	Antibody molecules binding to sars-cov-2
WO2024165710A1 (en)	2023-02-09	2024-08-15	Seni-Preps B.V.	Immunoglobulin single variable domains that inhibit urease and use thereof
KR20250133776A (ko)	2023-02-10	2025-09-08	아뮤닉스 파마슈티컬스, 인크.	전립선-특이적 막 항원(psma)을 표적화하는 조성물 및 이의 제조 방법 및 사용 방법
CN120712282A (zh)	2023-02-17	2025-09-26	阿布林克斯有限公司	结合新生儿fc受体的多肽
WO2024175787A1 (en)	2023-02-24	2024-08-29	Vrije Universiteit Brussel	Anti-inflammatory pannexin 1 channel inhibitors
AR132062A1 (es)	2023-03-06	2025-05-21	Beigene Switzerland Gmbh	Anticuerpos multiespecíficos anti-cd3 y métodos de uso
AR132064A1 (es)	2023-03-06	2025-05-21	Beigene Switzerland Gmbh	Anticuerpos anti-cldn6 y métodos de uso
AR132063A1 (es)	2023-03-06	2025-05-21	Beigene Switzerland Gmbh	Anticuerpos multiespecíficos anti-cldn6 y anti-cd3 y métodos de uso
WO2024184476A1 (en)	2023-03-07	2024-09-12	Institut Curie	Ung/udg inhibition in brca-associated cancer
WO2024184479A1 (en)	2023-03-08	2024-09-12	Institut National de la Santé et de la Recherche Médicale	Methods for the treatment of food allergy
AU2024234615A1 (en)	2023-03-14	2025-08-21	Odyssey Therapeutics, Inc.	Anti-cd25 antigen-binding proteins and uses thereof
US20240344078A1 (en)	2023-03-14	2024-10-17	Aarhus Universitet	Genetically altered nfr5 receptor kinases
WO2024194673A1 (en)	2023-03-21	2024-09-26	Institut Curie	Methods for the treatment of dedifferentiated liposarcoma
WO2024194401A1 (en)	2023-03-21	2024-09-26	Institut Curie	Vps4b inhibitor for use in methods for the treatment of hrd cancer
WO2024194402A1 (en)	2023-03-21	2024-09-26	Institut Curie	Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
AU2024240821A1 (en)	2023-03-23	2025-11-06	Bodhi Bio Llc	Compositions and methods for antigen-specific therapy
AU2024247861A1 (en)	2023-03-24	2025-11-06	Sanofi	Asthma treatment by blocking il-13 and tslp
EP4435005A1 (en)	2023-03-24	2024-09-25	Sanofi	Asthma treatment by blocking il-13 and tslp
WO2024200846A1 (en)	2023-03-30	2024-10-03	272BIO Limited	Gnrh-binding polypeptides and uses thereof
AU2024243709A1 (en)	2023-04-03	2025-11-06	Katholieke Universiteit Leuven	Blood-brain barrier crossing antibodies
WO2024213782A1 (en)	2023-04-13	2024-10-17	Institut Curie	Methods for the treatment of t-cell acute lymphoblastic leukemia
WO2024224323A1 (en)	2023-04-24	2024-10-31	King Abdullah University Of Science Of Technology	Compositions, systems and methods for multiplex detection of target biomarkers in a sample
WO2024226829A2 (en)	2023-04-26	2024-10-31	Yale University	Enpp3-binding molecules, compositions formed therefrom, and methods of use thereof for the treatment of cancer
TW202509060A (zh)	2023-05-08	2025-03-01	法商賽諾菲公司	免疫球蛋白單可變結構域的醣基化
WO2024231348A1 (en)	2023-05-11	2024-11-14	Vib Vzw	Slc4a4/nbce1 inhibitors
WO2024238565A1 (en)	2023-05-15	2024-11-21	Vor Biopharma Inc.	Egf-like module containing mucin-like hormone-like 2 (erm2) binding agents and methods of use thereof
AR132699A1 (es)	2023-05-17	2025-07-23	Odyssey Therapeutics Inc	Anticuerpos de dominio único modificados
WO2024243340A1 (en)	2023-05-23	2024-11-28	Sana Biotechnology, Inc.	Tandem fusogens and related lipid particles
WO2024240162A1 (en)	2023-05-23	2024-11-28	Shanghai Allygen Biologics Co., Ltd.	Pd-l1 and trop-2 targeting conjugates comprising effector molecules and uses thereof
WO2024251783A1 (en)	2023-06-05	2024-12-12	Sanofi	Predicting thermal stabilities of immunoglobulin single variable domains using machine-learning models
WO2024251826A1 (en)	2023-06-05	2024-12-12	Vib Vzw	Glyco-engineered antibody-drug-conjugates comprising an oxime linker
WO2024251981A1 (en)	2023-06-09	2024-12-12	Umc Utrecht Holding B.V.	Detecting and/or modulating susceptibility to btn2a1 and/or btn3a1 targeting therapeutics
WO2024251983A1 (en)	2023-06-09	2024-12-12	Merck Patent Gmbh	Il-18 mimetics
WO2024256527A1 (en)	2023-06-13	2024-12-19	Institut National de la Santé et de la Recherche Médicale	Use of a cxcl 10 inhibitor for the treatment of transplant vasculopathy
WO2024259305A1 (en)	2023-06-14	2024-12-19	The Broad Institute, Inc.	Vhh polypeptides that bind to mesothelin, compositions and methods of use thereof
WO2024261235A1 (en)	2023-06-22	2024-12-26	Ablynx Nv	Chimeric proteins for modulating cytokine receptor activity
WO2024261338A1 (en)	2023-06-22	2024-12-26	Ablynx Nv	Immunoglobulin single variable domains targeting pd-l1
WO2024261344A1 (en)	2023-06-23	2024-12-26	Vib Vzw	Novel binders targeting the multi-drug resistant pathogen acinetobacter baumannii
AR133108A1 (es)	2023-06-29	2025-08-27	Odyssey Therapeutics Inc	Proteínas de unión a antígeno anti-trailr2 y sus usos
EP4483951A1 (en)	2023-06-30	2025-01-01	Université de Liège	Single-domain antibody for inhibition of neutrophil elastase activity
WO2025008537A1 (en)	2023-07-05	2025-01-09	Ablynx Nv	Improved fcrn antagonists for treatment of igg-related diseases and disorders
WO2025007195A1 (en)	2023-07-05	2025-01-09	CSL Innovation Pty Ltd	Methods of treating or preventing a complication of sickle cell disease
TW202509078A (zh)	2023-07-07	2025-03-01	美商維里迪恩醫療股份有限公司	治療慢性甲狀腺眼病之方法
WO2025024645A1 (en)	2023-07-25	2025-01-30	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Rapid method for producing antibodies
WO2025032112A1 (en)	2023-08-08	2025-02-13	Institut National de la Santé et de la Recherche Médicale	Methods for the treatment of type 2-mediated diseases
WO2025032158A1 (en)	2023-08-08	2025-02-13	Institut National de la Santé et de la Recherche Médicale	Method to treat tauopathies
WO2025034806A1 (en)	2023-08-08	2025-02-13	Wisconsin Alumni Research Foundation	Single-domain antibodies and variants thereof against fibroblast activation protein
WO2025032213A1 (en)	2023-08-10	2025-02-13	Ose Immunotherapeutics	Identification of hla-dra as a ligand of clec-1 and uses thereof
WO2025036848A1 (en)	2023-08-11	2025-02-20	Wuxi Biologics (Shanghai) Co., Ltd.	Anti-muc16 antibodies and uses thereof
EP4512243A1 (en)	2023-08-21	2025-02-26	Kymab Limited	Binding molecules
TW202525843A (zh)	2023-09-04	2025-07-01	法商賽諾菲公司	用於治療表現磷脂醯肌醇蛋白聚糖-3之腫瘤的多肽
TW202530246A (zh)	2023-09-15	2025-08-01	愛爾蘭商歐賽爾普羅希那有限公司	細胞穿透劑及其用途
GB202314424D0 (en)	2023-09-20	2023-11-01	Cambridge Entpr Ltd	A conjugate
WO2025061919A1 (en)	2023-09-22	2025-03-27	Ablynx Nv	Bi- and multivalent albumin binders
WO2025068393A1 (en)	2023-09-27	2025-04-03	Institut Curie	Methods for the treatment of fibrotic related diseases
WO2025073765A1 (en)	2023-10-03	2025-04-10	Institut National de la Santé et de la Recherche Médicale	Methods of prognosis and treatment of patients suffering from melanoma
WO2025073890A1 (en)	2023-10-06	2025-04-10	Institut National de la Santé et de la Recherche Médicale	Method to capture circulating tumor extracellular vesicles
WO2025078418A1 (en)	2023-10-10	2025-04-17	Nano Tag Biotechnologies Gmbh	Humanized single-domain antibodies binding to epitope tags
WO2025078401A1 (en)	2023-10-11	2025-04-17	BioNTech SE	Agents and methods for targeted delivery of immune effector cells
WO2025078851A1 (en)	2023-10-11	2025-04-17	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Methods of treating cognitive deficit
TW202515903A (zh)	2023-10-12	2025-04-16	瑞士商百濟神州瑞士有限責任公司	手術前後基於抗ｐｄ－１之治療
NL2036011B1 (en)	2023-10-12	2025-04-30	Synapse Res Institute	Molecules for reversing anti-coagulant activity of direct oral anticoagulants
TW202530265A (zh)	2023-10-13	2025-08-01	美商奧迪希治療公司	抗cdh17抗原結合蛋白及其用途
WO2025093541A1 (en)	2023-10-31	2025-05-08	Ose Immunotherapeutics	Combination of interleukin 7 and tumour associated antigen vaccine
WO2025093683A1 (en)	2023-11-03	2025-05-08	Neuvasq Biotechnologies Sa	Wnt7 signaling agonists
WO2025099632A1 (en)	2023-11-08	2025-05-15	Sanofi	Cd25 based lysosomal degrader and uses thereof
WO2025109176A1 (en)	2023-11-22	2025-05-30	Exevir Bio Bv	Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same
US20250296991A1 (en)	2023-12-01	2025-09-25	Ablynx N.V.	Precision activated polypeptides
WO2025122634A1 (en)	2023-12-05	2025-06-12	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of tau-related disorders
WO2025125577A1 (en)	2023-12-14	2025-06-19	Vib Vzw	Antibodies against influenza b virus
WO2025136985A1 (en)	2023-12-17	2025-06-26	Viridian Therapeutics, Inc.	Compositions, doses, and methods for treatment of thyroid eye disease
WO2025132833A1 (en)	2023-12-20	2025-06-26	Institut National de la Santé et de la Recherche Médicale	Anti trypsin-3 single domain antibody
WO2025133253A2 (en)	2023-12-22	2025-06-26	Ablynx Nv	Protein-based conjugation carriers for intranuclear delivery
WO2025133252A1 (en)	2023-12-22	2025-06-26	Ablynx Nv	Immunoglobulin single variable domains targeting ceacam5
US20250236673A1 (en)	2023-12-22	2025-07-24	Ablynx N.V.	Protein-based carriers for site-specific amine conjugation
EP4574981A1 (en)	2023-12-22	2025-06-25	Biotalys NV	Anti-fungal vhh antibodies
WO2025151492A1 (en)	2024-01-09	2025-07-17	Viridian Therapeutics, Inc.	Compositions and methods for treatment of thyroid eye disease
WO2025151496A1 (en)	2024-01-09	2025-07-17	Viridian Therapeutics, Inc.	Compositions and methods for treatment of thyroid eye disease
WO2025151502A1 (en)	2024-01-09	2025-07-17	Viridian Therapeutics, Inc.	Modified antibodies
WO2025154056A1 (en)	2024-01-21	2025-07-24	Ibi-Ag Innovative Bio Insecticides Ltd.	Anti-insect cda nanobodies and uses thereof
WO2025154058A1 (en)	2024-01-21	2025-07-24	Ibi-Ag Innovative Bio Insecticides Ltd.	Anti-insect hsp70 nanobodies and uses thereof
WO2025160546A1 (en)	2024-01-26	2025-07-31	The Johns Hopkins University	Dendrimer conjugate compositions for intracellular delivery of antibodies and antibody fragments
WO2025162980A1 (en)	2024-01-30	2025-08-07	Institut National de la Santé et de la Recherche Médicale	Methods for the treatment of breast cancer using a jnk-1 inhibitor
WO2025168716A1 (en)	2024-02-07	2025-08-14	Eyebiotech Limited	Compositions, doses, and methods for treatment of ocular diseases
WO2025174825A2 (en)	2024-02-12	2025-08-21	Aera Therapeutics, Inc.	Delivery compositions
WO2025176777A1 (en)	2024-02-20	2025-08-28	Institut Curie	Dut inhibition in homologous recombination deficiency cancer
WO2025178959A1 (en)	2024-02-20	2025-08-28	University Of Georgia Research Foundation, Inc.	Single-domain antibodies and variants thereof against tab1
WO2025181155A1 (en)	2024-02-26	2025-09-04	Vib Vzw	Human beta-glucocerebrosidase binders and uses thereof
US20250361320A1 (en)	2024-02-27	2025-11-27	Bristol-Myers Squibb Company	Anti-ceacam5 antibodies and uses thereof
US20250269052A1 (en)	2024-02-27	2025-08-28	Bristol-Myers Squibb Company	Anti-ceacam5 antibody drug conjugates
WO2025191018A1 (en)	2024-03-13	2025-09-18	Institut National de la Santé et de la Recherche Médicale	Mrgpre binding agent for use in the treatment of inflammatory and pain disorders
WO2025196308A1 (en)	2024-03-22	2025-09-25	Vib Vzw	Means and methods for displaying fc-containing proteins on cells and selection thereof
WO2025207946A1 (en)	2024-03-28	2025-10-02	Genzyme Corporation	Polypeptides binding to a specific epitope of the transferrin receptor 1
WO2025212726A2 (en)	2024-04-04	2025-10-09	Compass Therapeutics, Inc.	Combination of antibodies targeting dll4/vegf and cd137 agonists or anti-pd1/anti-pd-l1 antibodies for the treatment of cancer
WO2025217240A1 (en)	2024-04-10	2025-10-16	Odyssey Therapeutics, Inc.	Anti-tnfr2 antigen-binding proteins and uses thereof
WO2025219231A1 (en)	2024-04-15	2025-10-23	Vib Vzw	Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope
WO2025226603A1 (en)	2024-04-22	2025-10-30	Surface Oncology, LLC	Methods for treating cancer using anti-ccr8 antibodies
WO2025224050A1 (en)	2024-04-22	2025-10-30	Institut National de la Santé et de la Recherche Médicale	Methods of treatment of patients suffering from hypomelanosis of ito
WO2025224297A1 (en)	2024-04-26	2025-10-30	Institut National de la Santé et de la Recherche Médicale	Antibodies having specificity to tgfbi and uses thereof
WO2025231143A1 (en)	2024-04-30	2025-11-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antibodies against ev-d68
WO2025240335A1 (en)	2024-05-13	2025-11-20	Regeneron Pharmaceuticals, Inc.	Fgfr3 binding molecules and methods of use thereof
WO2025238157A1 (en)	2024-05-15	2025-11-20	Katholieke Universiteit Leuven	Multispecific binding agent suitable for use in cancer immune therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8607679D0 (en) *	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
GB9016299D0 (en) *	1990-07-25	1990-09-12	Brien Caroline J O	Binding substances

1993
- 1993-08-18 ES ES05020889T patent/ES2325541T3/es not_active Expired - Lifetime
- 1993-08-18 AT AT00127968T patent/ATE420178T1/de active
- 1993-08-18 PT PT04077639T patent/PT1498427E/pt unknown
- 1993-08-18 DE DE69334305T patent/DE69334305D1/de not_active Expired - Lifetime
- 1993-08-18 DE DE69334308T patent/DE69334308D1/de not_active Expired - Lifetime
- 1993-08-18 EP EP93919098A patent/EP0656946B2/en not_active Expired - Lifetime
- 1993-08-18 PT PT93919098T patent/PT656946E/pt unknown
- 1993-08-18 ES ES93919098T patent/ES2162823T5/es not_active Expired - Lifetime
- 1993-08-18 EP EP05020889A patent/EP1621554B2/en not_active Expired - Lifetime
- 1993-08-18 EP EP09174252A patent/EP2192131A1/en active Pending
- 1993-08-18 AT AT04077639T patent/ATE452207T1/de active
- 1993-08-18 DK DK05008358.3T patent/DK1589107T3/da active
- 1993-08-18 AT AT93919098T patent/ATE203767T1/de active
- 1993-08-18 DE DE69334258T patent/DE69334258D1/de not_active Expired - Lifetime
- 1993-08-18 DK DK93919098.9T patent/DK0656946T4/da active
- 1993-08-18 AT AT05008358T patent/ATE452975T1/de active
- 1993-08-18 DE DE69330523T patent/DE69330523T4/de not_active Expired - Lifetime
- 1993-08-18 DE DE69334275T patent/DE69334275D1/de not_active Expired - Lifetime
- 1993-08-18 AU AU49497/93A patent/AU701578B2/en not_active Ceased
- 1993-08-18 PT PT00127968T patent/PT1087013E/pt unknown
- 1993-08-18 JP JP50590394A patent/JP3444885B2/ja not_active Expired - Fee Related
- 1993-08-18 WO PCT/EP1993/002214 patent/WO1994004678A1/en not_active Ceased
- 1993-08-18 CA CA002142331A patent/CA2142331C/en not_active Expired - Lifetime
- 1993-08-18 EP EP05008358A patent/EP1589107B1/en not_active Expired - Lifetime
- 1993-08-18 AT AT05020889T patent/ATE427968T1/de active
- 1993-08-18 DK DK05020889.1T patent/DK1621554T4/da active
- 1993-08-18 EP EP04077639A patent/EP1498427B1/en not_active Expired - Lifetime
- 1993-08-18 ES ES05008358T patent/ES2338791T3/es not_active Expired - Lifetime
- 1993-08-18 DK DK04077639.5T patent/DK1498427T3/da active
- 1993-08-18 DE DE69330523A patent/DE69330523D1/de not_active Expired - Lifetime
- 1993-08-18 ES ES00127968T patent/ES2322324T3/es not_active Expired - Lifetime
- 1993-08-18 ES ES04077639T patent/ES2338321T3/es not_active Expired - Lifetime
- 1993-08-18 PT PT05020889T patent/PT1621554E/pt unknown
- 1993-08-18 EP EP00127968A patent/EP1087013B1/en not_active Expired - Lifetime
- 1993-08-18 DK DK00127968T patent/DK1087013T3/da active
- 1993-08-18 PT PT05008358T patent/PT1589107E/pt unknown
1995
- 1995-02-20 FI FI950782A patent/FI115462B/fi not_active IP Right Cessation
- 1995-06-06 US US08/468,739 patent/US6015695A/en not_active Expired - Lifetime
- 1995-06-06 US US08/471,282 patent/US5840526A/en not_active Expired - Lifetime
- 1995-06-06 US US08/471,780 patent/US5759808A/en not_active Expired - Lifetime
- 1995-06-06 US US08/467,282 patent/US5800988A/en not_active Expired - Lifetime
- 1995-06-06 US US08/466,710 patent/US5874541A/en not_active Expired - Lifetime
2001
- 2001-05-07 JP JP2001136457A patent/JP3660270B2/ja not_active Expired - Lifetime
- 2001-10-25 GR GR20010401895T patent/GR3037024T3/el unknown
2004
- 2004-12-08 FI FI20041584A patent/FI117975B/fi not_active IP Right Cessation
2005
- 2005-01-18 JP JP2005010359A patent/JP4414900B2/ja not_active Expired - Lifetime
2007
- 2007-02-28 FI FI20070170A patent/FI120404B/fi not_active IP Right Cessation
2009
- 2009-08-21 JP JP2009192382A patent/JP2009280608A/ja active Pending

Also Published As

Publication number	Publication date
EP2192131A1 (en)	2010-06-02
US5840526A (en)	1998-11-24
CA2142331C (en)	2010-02-02
US6015695A (en)	2000-01-18
DE69330523T4 (de)	2012-08-23
PT1087013E (pt)	2009-04-15
ATE452207T1 (de)	2010-01-15
EP1621554B1 (en)	2009-04-08
FI117975B (fi)	2007-05-15
FI20041584L (fi)	2004-12-08
WO1994004678A1 (en)	1994-03-03
ATE452975T1 (de)	2010-01-15
DE69334305D1 (de)	2010-01-28
ATE427968T1 (de)	2009-04-15
AU4949793A (en)	1994-03-15
JP2002053600A (ja)	2002-02-19
ES2162823T5 (es)	2010-08-09
EP1589107A1 (en)	2005-10-26
DE69334275D1 (de)	2009-05-20
EP1621554B2 (en)	2012-08-29
US5874541A (en)	1999-02-23
EP0656946B2 (en)	2010-03-31
ES2322324T3 (es)	2009-06-19
EP1498427A1 (en)	2005-01-19
JPH08500487A (ja)	1996-01-23
DK1498427T3 (da)	2010-04-26
DK0656946T3 (da)	2001-11-05
DE69334308D1 (de)	2010-02-04
ES2162823T3 (es)	2002-01-16
DK1621554T3 (da)	2009-08-10
EP1621554A1 (en)	2006-02-01
EP1087013A2 (en)	2001-03-28
DE69330523T3 (de)	2010-10-28
DE69330523T2 (de)	2002-03-28
FI20070170L (fi)	2007-02-28
US5759808A (en)	1998-06-02
PT656946E (pt)	2001-12-28
EP1087013A3 (en)	2001-11-28
AU701578B2 (en)	1999-02-04
JP4414900B2 (ja)	2010-02-10
DK1621554T4 (da)	2012-12-17
CA2142331A1 (en)	1994-03-03
DE69334258D1 (de)	2009-02-26
ES2338791T3 (es)	2010-05-12
EP1087013B1 (en)	2009-01-07
FI950782A0 (fi)	1995-02-20
JP3444885B2 (ja)	2003-09-08
FI120404B (fi)	2009-10-15
ATE203767T1 (de)	2001-08-15
FI950782A7 (fi)	1995-04-20
EP1498427B1 (en)	2009-12-16
FI115462B (fi)	2005-05-13
DE69330523D1 (de)	2001-09-06
ES2338321T3 (es)	2010-05-06
ES2325541T3 (es)	2009-09-08
JP2009280608A (ja)	2009-12-03
DK0656946T4 (da)	2010-07-26
US5800988A (en)	1998-09-01
EP0656946A1 (en)	1995-06-14
PT1621554E (pt)	2009-07-13
GR3037024T3 (en)	2002-01-31
EP0656946B1 (en)	2001-08-01
PT1498427E (pt)	2010-03-22
DK1589107T3 (da)	2010-04-26
EP1589107B1 (en)	2009-12-23
JP2005170953A (ja)	2005-06-30
PT1589107E (pt)	2010-03-29
ATE420178T1 (de)	2009-01-15
JP3660270B2 (ja)	2005-06-15

Publication	Publication Date	Title
DK0656946T3 (da)	2001-11-05	Immunoglobuliner uden lette kæder
AU5647896A (en)	1996-11-18	Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DK0975771T3 (da)	2007-10-22	Fusionsproteiner af TGF-beta-receptortype II og immunoglobulins konstante region
ATE187494T1 (de)	1999-12-15	Multivalente einkettige antikörper
FI965032A0 (fi)	1996-12-16	Interleukiini-5-spesifisiä yhdistelmä-vasta-aineita
DE59209129D1 (de)	1998-02-19	Verwendung von Antikörper enthaltenden Präparationen zur Immunsuppression
DK0727436T3 (da)	1999-02-01	Monoklonale antistoffer (MAK) mod tumorassocierede antigener, deres fremstilling og anvendelse
FI934963A7 (fi)	1993-11-10	CTAA 81AV78, monoklonaalisen 81AV78-humaanivasta-aineen tunnistama ant igeeni